Author Archives: C Diff Foundation

November Is C. difficile Awareness Month With An Annual Conference, Recognizing Subject Matter Experts, Expressing Gratitude to US Governors

TAMPA, Fla. /ScoopCloud/ -- C Diff Foundation announced today that the 9th Annual International C. diff. Conference and Health EXPO welcomed over 40 international topic-experts dedicated in disciplines of healthcare, pharma, biotech, and academia on November 4-5, 2021. World-renowned presenters delivered data and discussed critical information on a leading Healthcare-Associated Infection (HAI), Clostridioides difficile with global healthcare-associated issues: 100% Live-online presentations.

The Conference registration was complimentary this year. To learn more about this extraordinary conference, guest speakers, and the diverse topics presented visit: https://www.cdiff2021.com

For conference coverage visit ContagionLive Infectious Diseases Today: https://www.contagionlive.com/latest-conference

On behalf of the C Diff Foundation, Sahil Khanna, M.B.B.S, M.S. proudly presented the Lifetime Achievement Award to Dale Gerding, MD, MACP, FIDSA, FSHEA for his outstanding vision, dedication, and commitment and for the advancement of Clostridioides difficile research, development, and care through the years. The Dale Gerding Lifetime Achievement award will be presented annually during the C Diff Foundation's November conference to a healthcare professional meeting the criteria, nominated by peers, and awarded by Dr. Gerding himself.

The C Diff Foundation "Making a Difference: Innovations in Infection Prevention" 2021 award was presented to PhoneSoap acknowledging their exceptional organization who is making a difference in the Infection Prevention community, with their innovative products, services, and technologies.

The award was accepted by Wes LaPorte, CEO of PhoneSoap. "PhoneSoap's mission has always been to limit the spread of infectious diseases through science and technology. We are honored to accept the Innovations in Infection Prevention award of 2021 from the C Diff Foundation given their very important endeavor to bring awareness, education, and advocacy globally," stated LaPorte.

According to the 2017 Update (published February 2018) of the Clinical Practice Guidelines for C. difficile Infection by the Infectious Diseases Society of America (IDSA) and Society or Healthcare Epidemiology of America (SHEA), CDI remains a significant medical problem in hospitals, in long-term care facilities and in the community. C. difficile is one of the most common causes of health care- associated infections in U.S. hospitals (Lessa, et al, 2015, New England Journal of Medicine). Recent estimates suggest C. difficile approaches 500,000 infections annually in the U.S. and is associated with approximately 20,000 deaths annually. (Guh, 2020, New England Journal of Medicine).

Based on internal estimates, the recurrence rate of two of the three antibiotics currently used to treat CDI is between 20% and 40% among approximately 150,000 patients treated. We believe the annual incidence of CDI in the U.S. approaches 600,000 infections and has a mortality rate of approximately 9.3%.

The C Diff Foundation expresses their gratitude to all the Sponsors and Keynote speakers for their generous support of the 9th Annual International C. diff. Conference and Health EXPO. Together we deliver superior educational up-to-date data, advance the healthcare professional knowledge and understanding of the topics discussed, and serve as the leading organization educating and advocating for C. difficile infection prevention, treatments, clinical trial, diagnostics, support, and environmental safety worldwide. We are grateful to be the leading resource for patients, families, caregivers, and healthcare professionals.

Many US Governors have signed a state proclamation proclaiming November 2021 as Clostridioides difficile (C. difficile, C. diff.) Infection Awareness Month.

"Our shared goal is to witness a significant increase in C. difficile awareness, with a noted reduction in C. difficile infections worldwide by the year 2025. We would also like to thank Seres Therapeutics, Rebiotix, a Ferring Company, and Ferring Pharmaceuticals for their efforts and support with this endeavor," stated Nancy C. Caralla, Executive Director of the C Diff Foundation.

About C Diff Foundation:

C Diff Foundation, a 501(c)(3) nonprofit, is the leading patient, caregiver, and healthcare organization educating and advocating for C. difficile (Clostridioides difficile, C. diff., CDI, CDAD) prevention, treatments, clinical trials, diagnostics, support, and environmental safety worldwide. Their Mission continues to move forward and grow through research conducted by government, industry, and academia strengthening the advocacy on behalf of patients, families, caregivers, healthcare professionals, and researchers worldwide.

For more information: https://cdifffoundation.org/

Follow C Diff Foundation:

Twitter @cdiffFoundation

#cdiff2021 #cdiffawarenessmonth

C Diff Foundation(TM) is a trademark of C Diff Foundation, established 2012 in the U.S.

C Diff Foundation announced today that the 9th Annual International C. diff. Conference and Health EXPO welcomed over 40 international topic-experts dedicated in disciplines of healthcare, pharma, biotech, and academia on November 4-5, 2021. World-renowned presenters delivered data and discussed critical information on a leading Healthcare-Associated Infection (HAI), Clostridioides difficile with global healthcare-associated issues: 100% Live-online presentations.

Related link: https://cdifffoundation.org/

9th Annual C. diff. Conference and Health EXPO Pushes Past COVID-19 and Embraces Virtual Technology to Provide Global Online Learning for Healthcare Professionals on Nov. 4-5

TAMPA, Fla. /ScoopCloud/ -- C Diff Foundation announced today that the 9th Annual International C. diff. Conference and Health EXPO is honored to welcome over 40 international topic-experts dedicated in disciplines of healthcare, pharma, biotech, and academia. World-renowned presenters will deliver data and discuss critical information on a leading Healthcare-Associated Infection (HAI), Clostridioides difficile with global healthcare-associated issues from 10 a.m. - 4 p.m. ET on Nov. 4 - 5, 2021: 100% Live-online presentations, on-demand poster presentations, exhibitors, and real-time networking opportunities available. Conference registration is complimentary this year.

To learn more about this extraordinary conference, guest speakers, and the diverse topics being presented visit https://www.cdiff2021.com.

All attendees will have the highest levels of peer networking and learning opportunity at the Conference and Health EXPO.

"The annual C Diff Foundation conference is a highlight of my learning year. The combination of academia, pharmaceutical, and governmental representation creates a learning environment that is second to none. I went initially in 2014 and have circled the conference dates on my calendar annually as immobile. The timing during C. difficile awareness month is tremendous as it summarizes all of the newest findings throughout the year," stated Paul Feuerstadt, MD, FACG, AGAF.

According to the 2017 Update (published February 2018) of the Clinical Practice Guidelines for C. difficile Infection by the Infectious Diseases Society of America (IDSA) and Society or Healthcare Epidemiology of America (SHEA), CDI remains a significant medical problem in hospitals, in long-term care facilities and in the community.

C. difficile is one of the most common causes of health care- associated infections in U.S. hospitals (Lessa, et al, 2015, New England Journal of Medicine). Recent estimates suggest C. difficile approaches 500,000 infections annually in the U.S. and is associated with approximately 20,000 deaths annually. (Guh, 2020, New England Journal of Medicine). Based on internal estimates, the recurrence rate of two of the three antibiotics currently used to treat CDI is between 20% and 40% among approximately 150,000 patients treated. We believe the annual incidence of CDI in the U.S. approaches 600,000 infections and has a mortality rate of approximately 9.3%.

The C Diff Foundation expresses their gratitude to Seres Therapeutics for being the conference Diamond Sponsor. Seres Therapeutics, Inc. is a leading microbiome therapeutics company developing a novel class of multifunctional bacterial consortia designed to functionally interact with host cells and tissues to treat disease. Seres' SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. The SER-109 program is being advanced for the treatment of recurrent C. difficile infection and has potential to become a first-in-class FDA-approved microbiome therapeutic. Seres is evaluating SER-301 in a Phase 1b study in patients with ulcerative colitis and SER-155 in a Phase 1b study to address gastrointestinal infections, bacteremia, and graft-versus-host disease. For more information, please visit https://www.serestherapeutics.com.

Their gratitude is also extended to Ferring Pharmaceuticals for being the Platinum Sponsor of the 9th Annual International C. diff. Conference and Health EXPO. Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and urology. Ferring is committed to exploring the crucial link between the microbiome and human health, beginning with the threat of recurrent C. difficile infection. With the 2018 acquisition of Rebiotix and several other alliances, Ferring is a world leader in microbiome research, developing novel microbiome-based therapeutics to address significant unmet needs and help people live better lives. For more information, please visit https://www.ferringusa.com.

About C Diff Foundation:

C Diff Foundation, a 501(c)(3) nonprofit, is the leading patient, caregiver, and healthcare organization educating and advocating for C. difficile (Clostridioides difficile, C. diff., CDI, CDAD) prevention, treatments, clinical trials, diagnostics, support, and environmental safety worldwide. Their Mission continues to move forward and grow through research conducted by government, industry, and academia strengthening the advocacy on behalf of patients, families, caregivers, healthcare professionals, and researchers worldwide. For more information: https://cdifffoundation.org/

Follow C Diff Foundation on Twitter @cdiffFoundation #cdiff2021 #cdiffawarenessmonth

C Diff Foundation(tm) is a trademark of C Diff Foundation, established 2012 in the U.S.

C Diff Foundation announced today that the 9th Annual International C. diff. Conference and Health EXPO is honored to welcome over 40 international topic-experts dedicated in disciplines of healthcare, pharma, biotech, and academia. World-renowned presenters will deliver data and discuss critical information on a leading Healthcare-Associated Infection (HAI), Clostridioides difficile with global healthcare-associated issues on Nov. 4 - 5, 2021.

Related link: https://cdifffoundation.org/

COVID Variants Do Not Stop C. diff. Awareness Walks Worldwide

TEANECK, N.J. /ScoopCloud/ -- C Diff Foundation announced today that the 5th Annual Global C. diff. Awareness Walks will take place on-demand, on a livestream, and in-person at Sims Park, New Port Richey, FL, and Brown Street Park Complex, Spring city, PA, and Milton A. Votee, Teaneck, NJ. This year's annual events will take place on Saturday, September 25, 2021, from 9 a.m. - 12 p.m. EDT. Learn more at: https://www.cdiffwalks.com

Proceeds from the events will benefit the C Diff Foundation's mission educating and advocating for C. difficile infection prevention, treatments, clinical trials, and environmental safety worldwide. During these unprecedented times the C Diff Foundation effectively adapts to overcome the many obstacles developing from this global virus and the variants of SARS-CoV-2 that have been emerging and circulating around the world throughout the COVID-19 pandemic.

C. diff. infections are one of the leading healthcare-associated infections facing local communities worldwide. According to the Centers for Disease Control and Prevention (CDC), a Clostridioides difficile infection (C. diff., C. difficile), (formally known as Clostridium difficile) "has become the most common microbial cause of healthcare-associated infections in U.S. hospitals and costs up to $4.8 billion each year in excess health care costs for acute care facilities alone." Statistics provided by the CDC suggest that C. difficile cause nearly 500,000 infections in patients in the U.S. annually. In one study noted by the CDC, among infected patients, nearly 29,000 died within 30 days of being diagnosed, and more than half of those deaths (15,000) were directly attributable to a C. difficile infection.

"C Diff Foundation volunteering members have a passion to improve the lives of patients, families, and caregivers who have been impacted by C. diff. infections worldwide," says Nancy C. Caralla, Founding President, Executive Director of the C Diff Foundation. "At the in-person C. diff. Awareness Walks, a safe distance will be maintained, and hand sanitizer will be available to ensure a safe outdoor event. 'Let's Walk' presents educational information shared by health care professionals, and C. diff. Survivors, through on-demand walks and livestream options located on the dedicated event website: https://cdiffwalks.com."

Thank you, Ferring Pharmaceuticals, for being the Global Sponsor of the 5th Annual Global C. diff. Awareness Walks. Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and urology. Ferring is committed to exploring the crucial link between the microbiome and human health, beginning with the threat of recurrent C. difficile infection. With the 2018 acquisition of Rebiotix and several other alliances, Ferring is a world leader in microbiome research, developing novel microbiome-based therapeutics to address significant unmet needs and help people live better lives. For more information visit https://www.ferringusa.com.

We also extend our thanks to Seres Therapeutics, Inc. for being the Diamond Sponsor of the 5th Annual Global C. diff. Awareness Walks.

Seres Therapeutics, Inc. is a leading microbiome therapeutics company developing a novel class of multifunctional bacterial consortia designed to functionally interact with host cells and tissues to treat disease. Seres' SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. The SER-109 program is being advanced for the treatment of recurrent C. difficile infection and has potential to become a first-in-class FDA-approved microbiome therapeutic. Seres is evaluating SER-301 in a Phase 1b study in patients with ulcerative colitis and SER-155 in a Phase 1b study to address gastrointestinal infections, bacteremia and graft-versus-host disease. For more information, please visit https://www.serestherapeutics.com.

About C Diff Foundation:

C Diff Foundation, a 501(c)(3) nonprofit, is the leading patient and healthcare organization educating and advocating for C. difficile (Clostridioides difficile, C. diff., CDI, CDAD) prevention, treatments, clinical trials, diagnostics, support, and environmental safety worldwide. Their Mission continues to move forward and grow through research conducted by government, industry, and academia strengthening the advocacy on behalf of patients, families, caregivers, healthcare professionals, and researchers worldwide. For more information: https://cdifffoundation.org/

Follow C Diff Foundation:

Twitter @cdiffFoundation

#cdiffwalks2021 #cdiff2021

C Diff Foundation(tm) is a trademark of C Diff Foundation, established 2012 in the U.S.

MEDIA CONTACT:

Kathy Bischoff, Global Walk Committee

kathy@cdifffoundation.org

(727) 205-3922

MULTIMEDIA:

IMAGE link for media: https://www.Send2Press.com/300dpi/21-0920s2p-cdf-events-300dpi.jpg

C Diff Foundation announced today that the 5th Annual Global C. diff. Awareness Walks will take place on-demand, on a livestream, and in-person at Sims Park, New Port Richey, FL, and Brown Street Park Complex, Spring city, PA, and Milton A. Votee, Teaneck, NJ. This year's annual events will take place on Saturday, September 25, 2021, from 9 a.m. - 12 p.m. EDT.

Related link: https://cdifffoundation.org/

Live-Online C. diff. Symposium developed to support and guide patients, families, and caregivers through a C. difficile illness

TAMPA, Fla. /ScoopCloud/ -- The C Diff Foundation will host a free, live-online, and interactive symposium on Friday, July 16, 2021, from 1 to 3 p.m. EDT. Sponsored by Seres Therapeutics, the event is designed for patients who are being treated for a C. diff. infection (CDI) in addition to those who are recovering or who have experienced CDI recurrences. The patients, family members, and caregivers will all benefit from the information and up-to-date data presented.

Presenters are among some of the top C diff. thought leaders and include healthcare professionals, practitioners, and educators who are helping to change the way individuals maneuver through a C. difficile infection, worldwide.

Unlike other presentations on this topic, C. diff. Survivors will share their C. diff. infection journeys to provide a real-world perspective on the patient experience. Other topics addressed will include creating a culture for patient-centered care, C. diff. innovations, diagnostics, research, environmental safety, clinical trials, and studies, C diff. in pediatric patients and more.

To register for this global live-online event, visit: https://cdifffoundation.org/patient-family-caregiver-symposium-july-16-2021/

About Clostridioides difficile Infection (CDI)

Clostridioides (formerly Clostridium) difficile, also known as C. difficile, C. diff., is one of the most common cause and leading healthcare-associated infection in U.S. hospitals (Lessa, et al, 2015, New England Journal of Medicine). Recent estimates suggest C. difficile approaches 500,000 infections annually in the United States and is associated with approximately 20,000 deaths. (Guh, 2020, New England Journal of Medicine). Based on internal estimates including a recurrence rate of approximately 20 percent, the C Diff Foundation believes that the annual incidence in the U.S. approaches 600,000.

About Seres Therapeutics

Seres Therapeutics is a late-clinical stage biotechnology company with a strong development pipeline and rigorous scientific underpinning, working to revolutionize treatment of a wide range of diseases by modulating the function of the human microbiome.

It reported positive, topline results from the pivotal Phase 3 ECOSPOR III study evaluating its investigational oral microbiome therapeutic SER-109 for recurrent C. difficile infection (CDI).

For more information: https://www.serestherapeutics.com/

About the C Diff Foundation

C Diff Foundation, a 501(c)(3) nonprofit, is the leading patient and healthcare organization educating and advocating for C. difficile (Clostridioides difficile, C. diff., CDI, CDAD) prevention, treatments, clinical trials, diagnostics, support, and environmental safety worldwide. Their Mission continues to move forward and grow through research conducted by government, industry, and academia strengthening the advocacy on behalf of patients, families, caregivers, healthcare professionals, and researchers worldwide.

For more information: https://cdifffoundation.org/

Follow C Diff Foundation:

Twitter @cdiffFoundation #cdiffpatientfamilycaregiver #cdiff2021 #cdiffwalks2021

C Diff Foundation(TM) is a trademark of the C Diff Foundation, established 2012 in the U.S.

The C Diff Foundation will host a free, live-online, and interactive symposium on Friday, July 16, 2021, from 1 to 3 p.m. EDT. Sponsored by Seres Therapeutics, the event is designed for patients who are being treated for a C. diff. infection (CDI) in addition to those who are recovering or who have experienced CDI recurrences.

Related link: https://cdifffoundation.org/

A three-time C. diff. Survivor and Registered Dietician publish book for patients, families, and caregivers impacted by Clostridioides difficile

TAMPA, Fla. /ScoopCloud/ -- In the new book, "Managing a C. difficile Infection: For Patients, Families, and Caregivers" (ISBN: 979-8519789851), Nancy C. Caralla, three-time C. diff. Survivor, Founding President, Executive Director of the C Diff Foundation, and Karen F. Factor, MS, RD. LDN, Nutrition Wellness Chairperson of the C Diff Foundation share their knowledge and experience with patients, family members, and caregivers who have been impacted by a C. difficile infection (CDI) and CDI recurrences.

The book will answer the many questions focused on C. difficile infections, C. difficile prevention, home environment cleaning, nutrition, while introducing the readers to the microbiome and clinical trials.

About Clostridioides difficile Infection (CDI)

Clostridioides (formerly Clostridium) difficile, also known as C. difficile, C. diff., is one of the most common cause and leading healthcare-associated infection in U.S. hospitals (Lessa, et al, 2015, New England Journal of Medicine). Recent estimates suggest C. difficile approaches 500,000 infections annually in the United States and is associated with approximately 20,000 deaths. (Guh, 2020, New England Journal of Medicine). Based on internal estimates including a recurrence rate of approximately 20%, we believe the annual incidence in the U.S. approaches 600,000.

About the Authors

Nancy C Caralla, Founding President, and Executive Director of the C Diff Foundation is a three-time Clostridioides difficile infection (C. diff., C. difficile) survivor. She has accumulated over 25 years of experience in the nursing profession blended with over 25 years of experience in international construction management. Over the past several years, Nancy, in partnership with the C Diff Foundation members, focuses on raising C. difficile awareness through education and advocating for Clostridioides difficile infection prevention, treatments, clinical trials, and environmental safety worldwide.

Karen F. Factor, Registered Dietitian (RD), C Diff Foundation's Chairperson of the Nutrition and Wellness Committee, is uniquely trained in the science of nutrition and practice of dietetics to design and provide medical nutrition therapy (MNT) and other evidence-based applications of the Nutrition Care Process (NCP) that exemplify the profession's systematic approach to providing high-quality nutrition care to individuals experiencing dietary challenges, especially during a CDI.

About the C Diff Foundation

The C Diff Foundation, a 501(c)(3) non-profit, founded in 2012 with a global mission educating and advocating for C. diff. infection (CDI) prevention, treatments, clinical trials, environmental safety, and support. The C Diff Foundation(tm) is the leading global patient advocacy organization.

Their mission continues moving forward and growing through research conducted by government, industry, and academia strengthening the advocacy on behalf of patients, healthcare professionals, and researchers worldwide.

For more information: https://cdifffoundation.org/

MEDIA CONTACT:
Kathy Bischoff
of C Diff Foundation
+1-727-205-3922
kathy@cdifffoundation.org

MULTIMEDIA:

*PHOTO Link for media: https://www.Send2Press.com/300dpi/21-0628s2p-cdiff-book-300dpi.jpg

*Caption: Cover, "Managing a C. difficile Infection: For Patients, Families, and Caregivers" (ISBN: 979-8519789851).

In the new book, "Managing a C. difficile Infection: For Patients, Families, and Caregivers" (ISBN: 979-8519789851), Nancy C. Caralla, three-time C. diff. Survivor, Founding President of the C Diff Foundation, and Karen F. Factor, MS, RD. LDN, Nutrition Wellness Chairperson, share their knowledge and experience with patients, family members, and caregivers who have been impacted by a CDI infection.

Related link: https://cdifffoundation.org/

C Diff Foundation Releases ‘C diff and You’ App for Patients, Families, and Caregivers

TAMPA, Fla. /ScoopCloud/ -- C Diff Foundation, the leading Global Patient and Healthcare Organization Educating and Advocating for C. difficile (Clostridioides difficile, C. diff., CDAD, CDI) today announced that the organization has developed a free mobile application designed specifically for patients and families who have been impacted by a Clostridioides difficile infection.

The free app, "C diff and You," is available on the Apple Store and Google Play, and was designed by the C Diff Foundation as an interactive educational tool allowing users to access easy-to-understand information about C. diff. infection prevention, treatments, clinical trials, support, nutrition, diagnostics, and environmental safety.

Clostridioides difficile infection, also called C. diff., CDI, C. difficile, or CDAD, is a life-threatening infection.

"I am really pleased to see this further addition to the C Diff Foundation's catalogue of achievements. This is an ideal way to communicate information far and wide," stated Professor Mark Wilcox, MD, FRCPath.

"There are patients, families, and caregivers isolated, and experiencing social-economic changes resulting from the COVID-19 pandemic. In the Global efforts to slow the spread of the COVID-19 virus the ramifications being witnessed range from loss of wages to difficulties meeting housing, utilities, nutrition, and healthcare expenses down to basic cable and internet connections. The one common denominator remaining accessible is the Mobile (also called Cell) phone. Developing the mobile application, 'C diff and You,' places the C. diff. community in the palm of their hands continuing to support the patients, families, and caregivers who desperately need to know that they are not alone no matter where they are," says Nancy C. Caralla, Founding President, and Executive Director of the C Diff Foundation.

Through the deployment of this app, the C Diff Foundation continues with its commitment to evolve resources to unite patients, families, and healthcare providers in the fight against C. diff. infections. The app focuses on quality resources directly relevant to patients and their care providers, aiming to lower the anxiety and fear associated with a CDI and provide easy access to reliable information to all users. "C diff and You" will also provide users with direct access to patient-centered care information, educational episodes of the "C. diff. Spores and More" archived radio episodes, and the C. diff. Global Tele-Support Network with a one tap key to "Sign Up Today" for Caregiver, Nutrition, and Physician support sessions. The telephone access key connects the app user directly to the C Diff Foundation office and the Foundation's Triage Nurses.

"Patients with a C. difficile infection are in desperate need for education on the risk factors for the infection, how to stop infection spread, the chances of recurrence, and treatment options for recurrent C. difficile. The 'C diff and You' app is an outstanding and user-friendly platform for patients to get accurate information on C. difficile infection and has resources that patients can use," says Sahil Khanna, M.B.B.S., M.S.

About Clostridioides difficile Infection (CDI)

Clostridioides (formerly Clostridium) difficile, also known as C. difficile, C. diff., is one of the most common cause and leading healthcare-associated infection in U.S. hospitals (Lessa, et al, 2015, New England Journal of Medicine). Recent estimates suggest C. difficile approaches 500,000 infections annually in the United States and is associated with approximately 20,000 deaths. (Guh, 2020, New England Journal of Medicine). Based on internal estimates including a recurrence rate of approximately 20%, we believe the annual incidence in the U.S. approaches 600,000.

About the C Diff Foundation

C Diff Foundation, a 501(c)(3) nonprofit, is the leading patient and healthcare organization educating and advocating for C. difficile (Clostridioides difficile, C. diff., CDI, CDAD) prevention, treatments, clinical trials, diagnostics, support, and environmental safety worldwide. Their Mission continues to move forward and grow through research conducted by government, industry, and academia strengthening the advocacy on behalf of patients, families, caregivers, healthcare professionals, and researchers worldwide.

For more information: https://cdifffoundation.org/

Follow C Diff Foundation:

Twitter @cdiffFoundation
#cdiffpatientfamilycaregiver #cdiff2021 #cdiffwalks2021

C Diff Foundation™ is a trademark of The C Diff Foundation, established 2012 in the U.S.

C Diff Foundation, the leading Global Patient and Healthcare Organization Educating and Advocating for C. difficile (Clostridioides difficile, C. diff., CDAD, CDI) today announced that the organization has developed a free mobile application designed specifically for patients and families who have been impacted by a Clostridioides difficile infection.

Related link: https://cdifffoundation.org/

C Diff Foundation Hosts Live-Online Symposium for Patients, Families and Caregivers

TAMPA, Fla. /ScoopCloud/ -- The C Diff Foundation will host a free, live-online, and interactive symposium on Friday, Jan. 15 from 1 to 4 p.m. EST. Sponsored by Seres Therapeutics, the event is designed for patients who are being treated for a C. diff. infection in addition to those who are recovering or who have experienced recurrences. The patients, family members and caregivers will all benefit from the information and up-to-date data presented.

Presenters are among some of the top C diff. thought leaders and include healthcare professionals, practitioners, educators and patients who are transforming the patient experience, and changing the way people experience C. diff. infections, worldwide.

Unlike other presentations on this topic, patients will share their C. diff. infection journeys, providing a real-world perspective on the patient experience. Other topics addressed will include creating a culture for patient-centered care, C. diff. innovations, diagnostics, research, environmental safety, clinical trials and studies, C diff. in pediatric patients and more.

All presentations will be designed for the lay person to easily understand and attendees will be able to ask questions directly to the keynote speakers via a live chat feature after each presentation.

"The live chat feature is one we're excited about and believe the attendees will embrace to have their questions answered by the keynote speakers," Nancy Caralla, C Diff Foundation founding president and executive director, says.

To register for this global event, visit: https://cdifffoundation.org/patientfamilyevent/

About Clostridioides difficile Infection (CDI)

Clostridioides (formerly Clostridium) difficile, also known as C. difficile, C. diff., is one of the most common cause and leading healthcare-associated infection in U.S. hospitals (Lessa, et al, 2015, New England Journal of Medicine). Recent estimates suggest C. difficile approaches 500,000 infections annually in the United States and is associated with approximately 20,000 deaths. (Guh, 2020, New England Journal of Medicine). Based on internal estimates including a recurrence rate of approximately 20 percent, the C Diff Foundation believes that the annual incidence in the U.S. approaches 600,000.

About the C Diff Foundation

The C Diff Foundation, a 501(c)(3) non-profit, founded in 2012 with a global mission educating and advocating for C. diff. infection (CDI) prevention, treatments, clinical trials, environmental safety and support. Its mission continues to move forward and grow through research conducted by government, industry and academia strengthening the advocacy on behalf of patients, healthcare professionals and researchers, worldwide.

For more information: https://cdifffoundation.org/

About Seres Therapeutics

Seres Therapeutics is a late-clinical stage biotechnology company with a strong development pipeline and rigorous scientific underpinning, working to revolutionize treatment of a wide range of diseases by modulating the function of the human microbiome.

The Seres Therapeutics organization reported positive, topline results from the pivotal Phase 3 ECOSPOR III study evaluating its investigational oral microbiome therapeutic SER-109 for recurrent C. difficile infection (CDI).

For more information: https://www.serestherapeutics.com/

MULTIMEDIA:

IMAGE link for media: https://www.Send2Press.com/300dpi/21-0113s2p-cdiff-symposium-300dpi.jpg

Caption: Register for the Patient and Family C Diff Foundation Symposium

MEDIA CONTACT:
Kathy Bischoff
of C Diff Foundation
+1-727-205-3922
kathy@cdifffoundation.org

The C Diff Foundation will host a free, live-online, and interactive symposium on Friday, Jan. 15 from 1 to 4 p.m. EST. Sponsored by Seres Therapeutics, the event is designed for patients who are being treated for a C. diff. infection in addition to those who are recovering or who have experienced recurrences. The patients, family members and caregivers will all benefit from the information and up-to-date data presented.

Related link: https://cdifffoundation.org/

The C Diff Foundation Assures Patients C. diff. Clinical Trials Continue to Move Forward Safely

TAMPA, Fla. /ScoopCloud/ -- While some patients diagnosed with Clostridioides difficile (C. diff., C. difficile, CDI) believe they have run into clinical trial roadblocks, due to the recent focus on the pandemic, the C Diff Foundation wants them to know they are not out of options. Safe and active clinical trials continue.

Most Clinical trial sites have implemented protocols to disinfect, clean and maintain environmental safety for all visitors. Telehealth is also being utilized between healthcare professionals and patients who choose to participate in clinical trials.

C. diff. continues to be a leading cause of infectious disease deaths and in the U.S., nearly half a million Americans suffer from it, according to the CDC. It's important for patients to know that research is still happening to combat this infectious disease.

Even during these unprecedented times, clinical trials continue to press onward to resolve CDI's. The C Diff Foundation's mission in educating and advocating for Clostridioides difficile awareness, prevention, treatments, diagnostics, clinical trials, and environmental safety, forges ahead utilizing live, and pre-recorded media to reach health care professionals, patients, families, and caregivers worldwide.

For more information, call the C Diff Foundation at: 727-205-3922, or email: info@cdifffoundation.com.

C Diff Foundation: https://cdifffoundation.org/.

Clinical trial information: https://clinicaltrials.gov/ and https://cdiffclinicaltrials.com/

About ClinicalTrials.gov

ClinicalTrials.gov is a Web-based resource that provides patients, their family members, health care professionals, researchers, and the public with easy access to information on publicly and privately supported clinical studies on a wide range of diseases and conditions.

About the C Diff Foundation

The C Diff Foundation, a 501(c)(3) non-profit, founded in 2012 with a global mission of providing education for C. difficile infection prevention, treatments, environmental safety and support through research being conducted by the government, industry, and academia and provide better advocacy on behalf of patients, healthcare professionals, and researchers worldwide.

MEDIA CONTACT:
Kathy Bischoff
of C Diff Foundation
+1-727-205-3922
kathy@cdifffoundation.org

*LOGO link for media: https://www.Send2Press.com/300dpi/21-0111s2p-cdiff-clinical-300dpi.jpg

While some patients diagnosed with Clostridioides difficile (C. diff., C. difficile, CDI) believe they have run into clinical trial roadblocks, due to the recent focus on the pandemic, the C Diff Foundation wants them to know they are not out of options. Safe and active clinical trials continue.

Related link: https://cdifffoundation.org/

Leading Healthcare-Associated Infection Clostridioides difficile Symposium Focuses on Patients, Families, and Caregivers

TAMPA, Fla. /ScoopCloud/ -- C Diff Foundation announced today that the Inaugural Patient, Family, and Caregiver C. diff. Live Virtual Symposium will be hosted on November 23, 2020 at 1 p.m.-4 p.m. EST with keynote topic-experts dedicated in disciplines of healthcare, pharma, biotech, and academia. The event is complimentary with online registration http://www.cdifffoundation.org/

Presenters will deliver data and discuss critical information for an audience of individuals diagnosed and recovering from a C. difficile infection. The symposium was developed to increase awareness, expand the knowledge, and elevate advocacy skills through presentations focused on a leading Healthcare-Associated Infection (HAI) Clostridioides difficile Prevention, Treatments, Clinical Trials, Diagnostics, and Environmental Safety for Adults and Children.

C Diff Foundation expresses their gratitude to Seres Therapeutics for being the Sponsor of the Patient and Family Symposium and for partnering with the C Diff Foundation raising C. diff. awareness.

Seres Therapeutics partners with the C Diff Foundation to support this important event focused on the patients and their families who are so deeply affected by this devastating infection.

The C diff Foundation's Founding President, Executive Director, Nancy C. Caralla, a three-time C. diff. Survivor, devotes countless hours day in and day out with the members of the C Diff Foundation. As a global resource, the members of the C Diff Foundation are doing all that they can to support the educational needs of patients worldwide. It is through episodes on C. diff. Spores and More live broadcasts, the annual Symposium, and Conference that give a voice to the patients who have suffered through multiple recurrences by including these speakers in the section of the program entitled "Survivor's Journey." Only through the patient's eyes can we begin to truly understand their experiences, and the unmet needs.

About Clostridioides Difficile Infection (CDI)

Clostridioides (formerly Clostridium) difficile, also known as C. difficile or C. diff., is one of the most common causes of healthcare-associated infections in U.S. hospitals (Lessa, et al, 2015, New England Journal of Medicine). Recent estimates suggest C. difficile approaches 500,000 infections annually in the United States and is associated with approximately 20,000 deaths. (Guh, 2020, New England Journal of Medicine). Based on internal estimates including a recurrence rate of approximately 20%, we believe the annual incidence in the U.S. approaches 600,000.

About Seres Therapeutics:

Seres Therapeutics is a late-clinical stage biotechnology company with a strong development pipeline and rigorous scientific underpinning, working to revolutionize treatment of a wide range of diseases by modulating the function of the human microbiome.

About C Diff Foundation:

C Diff Foundation, a 501(c)(3) established 2012, comprised of 100% volunteering professionals is dedicated at supporting public health through education and advocating for Clostridioides difficile infection (CDI) prevention, treatments, clinical trials, AMR, Microbiome, and environmental safety worldwide.

Listen to "C.diff. Spores and More" Tuesdays at 1 p.m. EST (www.cdiffradio.com) sponsored by Clorox Healthcare.

Learn more at: https://cdifffoundation.org/.

Follow C Diff Foundation on LinkedIn, Twitter, Facebook

Twitter @cdiffFoundation #Cdiffpatientsfamily2020

Media Contact:
Kathy Bischoff
C Diff Foundation
kathy@cdifffoundation.org
Office: (727) 205-3922

*IMAGE link for media: https://www.Send2Press.com/300dpi/20-1119s2p-cdiff-symposium-300dpi.jpg

C Diff Foundation announced today that the Inaugural Patient, Family, and Caregiver C. diff. Live Virtual Symposium will be hosted on November 23, 2020 at 1 p.m.-4 p.m. EST with keynote topic-experts dedicated in disciplines of healthcare, pharma, biotech, and academia. The event is complimentary with online registration.

Related link: https://cdifffoundation.org/

2020 International Clostridioides difficile (C. diff., C. difficile) Virtual Conference and Health EXPO Nov. 14

TAMPA, Fla. /ScoopCloud/ -- C Diff Foundation announced today that the 8th Annual International C. diff. Virtual-Online Conference and Health EXPO will be a 5-1/2 hour online program with over fourteen international topic-experts dedicated in disciplines of healthcare, pharma, biotech, academia, and Government agencies.

Presenters will deliver data and discuss critical information on a leading Healthcare-Associated Infection (HAI), Clostridioides difficile, Gut Microbiome, Infection Prevention, and global healthcare-associated issues on November 14, 2020 with a live online program under the direction of IT professionals at WhiteHat Communications.

To learn more about this extraordinary conference, guest speakers, poster presentations, and the diverse topics being presented visit: https://cdiff2020.com/guest-speakers-1

All attendees will have the highest levels of online networking and learning opportunity at the Conference and Health EXPO and registration is complimentary this year. Save the date: November 4th and 5th, 2021 the 9th Annual conference will be hosted at the Boston Logan Hilton Hotel in Boston, Mass.

C Diff Foundation expresses their gratitude to Seres Therapeutics for being the conference Diamond Sponsor. Seres Therapeutics is appreciated for their continued support and partnering with the C Diff Foundation in promoting C. diff. Awareness worldwide. This activity has been supported by a medical educational Grant from Pfizer and the members of the C Diff Foundation are profoundly grateful.

Attendee Paul Feuerstadt, MD, FACG, AGAF stated "The level of detail and data presented has a wonderful balance for those with an interest in the scientific research and interested in the infection but also exceeds the expectations for those who are experts in the field wanting to share and exchange ideas with other thought leaders."

"I am excited to virtually meet and interact with everyone for the online extraordinaire C difficile foundation 2020 meeting. We will discuss all things C difficile and remember to tune in for my talk on the excitement of microbiome therapeutics for recurrent C difficile," stated Sahil Khanna, M.B.B.S., M.S.

The scientific data will be delivered through live virtual presentations and poster presentations at the 8th Annual International C. diff. Virtual Conference and Health Expo https://cdiff2020.com which coincides with the proclaimed; "November is Clostridioides difficile (C. diff., C. difficile) Awareness Month."

Scott Battles, VP of the C Diff Foundation stated, "We are profoundly grateful to the United States Governors for supporting our mission, along with our domestic and international partners."

November 18 - 24, 2020 Be Antibiotics Aware, a CDC educational effort, complements U.S. Antibiotic Awareness Week by providing partners with up-to-date information to help improve human antibiotic prescribing and use in the United States.

"None of us can do this alone, all of us can do this together."

About Clostridioides Difficile Infection (CDI)

Clostridioides (formerly Clostridium) difficile, also known as C. difficile or C. diff., is one of the most common causes of healthcare-associated infections in U.S. hospitals (Lessa, et al, 2015, New England Journal of Medicine). Recent estimates suggest C. difficile approaches 500,000 infections annually in the United States and is associated with approximately 20,000 deaths. (Guh, 2020, New England Journal of Medicine). Based on internal estimates including a recurrence rate of approximately 20%, we believe the annual incidence in the U.S. approaches 600,000.

About The C Diff Foundation:

C Diff Foundation, a 501(c)(3) established 2012, comprised of 100% volunteering professionals is dedicated at supporting public health through education and advocating for Clostridioides difficile infection (CDI) prevention, treatments, clinical trials, AMR, and environmental safety worldwide.

Listen to "C.diff. Spores and More" Tuesdays at 1 p.m. EST (www.cdiffradio.com) sponsored by Clorox Healthcare.

Learn more at: https://cdifffoundation.org/.

Follow C Diff Foundation on LinkedIn, Twitter, Facebook, and Instagram. Download "C diff and You" app from Apple and Google Stores.

Twitter @cdiffFoundation #Cdiff2020

Media Contact:
Kathy Bischoff
C Diff Foundation
kathy@cdifffoundation.org
Office: (727) 205-3922

IMAGE LINKS FOR MEDIA:

[1] https://www.Send2Press.com/300dpi/30-1111s2p-cdiff8th-splash-300dpi.jpg

[2] https://www.Send2Press.com/300dpi/20-1111s2p-Cdiff640-920Conf-300dpi.jpg

C Diff Foundation announced today that the 8th Annual International C. diff. Virtual-Online Conference and Health EXPO will be a 5-1/2 hour online program with over fourteen international topic-experts dedicated in disciplines of healthcare, pharma, biotech, academia, and Government agencies.

Related link: https://cdifffoundation.org/

C Diff Foundation Hosts 4th Annual Global C. diff. Awareness 2K Virtual Walks

TEANECK, N.J. /ScoopCloud/ -- C Diff Foundation announced today that registration is open for the 4th Annual Global C. diff. Awareness 2K Virtual Walks. This year's annual events will take place online and will be recorded at the Morris A. Votee Park, Teaneck, NJ, Charlestown Township Park, Phoenixville, PA, Sims Park, New Port Richey, FL on Saturday, September 12, 2020 from 8 a.m. - 12 p.m. ET. There will also be a superhero virtual show for super kids. Dr. Martha Clokie, Ph.D. will be leading the walk which will be recorded in Leicester, UK on Friday, September 11, 2020.

Registration is $20 per walker and complimentary for children 10 years of age and under. Learn more: https://cdifffoundation.org/cdiffwalk2020/

All registered awareness walkers will receive a t-shirt, giveaways, and educational material. Proceeds from the events will benefit the C Diff Foundation's mission educating and advocating for C. difficile infection prevention, treatments, clinical trials, and environmental safety worldwide. During these unprecedented times, caused by the COVID-19 pandemic, the C Diff Foundation effectively adapts to overcome the many obstacles developing from this global virus.

C. diff. infections are one of the leading healthcare-associated infections facing local communities worldwide. According to the Centers for Disease Control and Prevention (CDC), a Clostridioides difficile infection (C. diff., C. difficile), (formally known as Clostridium difficile) "has become the most common microbial cause of healthcare-associated infections in U.S. hospitals and costs up to $4.8 billion each year in excess health care costs for acute care facilities alone."

Statistics provided by the CDC suggest that C. difficile cause nearly 500,000 infections in patients in the U.S. annually. In one study noted by the CDC, among infected patients, nearly 29,000 died within 30 days of being diagnosed, and more than half of those deaths (15,000) were directly attributable to a C. difficile infection.

"Every day the C Diff Foundation members work to educate and advocate for C. difficile infection prevention, treatments, clinical trials, and environmental safety while providing support worldwide," says Nancy Caralla, Founding President, and Executive Director of the C Diff Foundation. "Our dedication to the cause is making a difference as we share a common goal with government agencies and health care organizations witnessing a decrease in newly diagnosed C.diff. infections and saving lives. Our dedicated volunteering members, around the globe, are focused on improving the lives of individuals and families who are impacted by C. diff. infections."

We sincerely thank Vedanta Biosciences, Inc. for being the Diamond Sponsor of the 4th Annual Global C. diff. Awareness 2K Virtual Walks. Vedanta Biosciences, Inc. is dedicated to finding treatments for patients with serious infections and immune diseases. Vedanta develops medicines made of consortia of bacterial strains which are selected to effect robust and durable changes in a patient's gut microbiota.

In contrast to fecal transplants or administration of fecal fractions, Vedanta's medicines are pure, uniform compositions of bacteria manufactured from clonal cell banks, bypassing the need to rely on direct sourcing of fecal donor material of inconsistent composition. Vedanta is currently enrolling patients with recurrent C. difficile infections (CDI) in its CONSORTIUM study to evaluate VE303, an investigational treatment for CDI.

About the C Diff Foundation:

The C Diff Foundation, a 501(c)(3) supports public health through educating and advocating for C. difficile infection prevention, treatments, clinical trials, and environmental safety worldwide. For more information, or to find out how you can be a host of a Global C.diff. Awareness 2K Walk, visit http://www.cdifffoundation.org.

Follow C Diff Foundation on Twitter: @cdiffFoundation #CdiffWalk2020

Media Contact:
Kathy Bischoff, Global Walk Committee
kathy@cdifffoundation.org

*IMAGE LINK FOR MEDIA: https://www.Send2Press.com/300dpi/20-0819s2p-Cdiff-WALK-300dpi.jpg

C Diff Foundation announced today that registration is open for the 4th Annual Global C. diff. Awareness 2K Virtual Walks. This year's annual events will take place online and will be recorded at the Morris A. Votee Park, Teaneck, NJ, Charlestown Township Park, Phoenixville, PA, Sims Park, New Port Richey, FL on Saturday, September 12, 2020 from 8 a.m. - 12 p.m. ET.

Related link: https://cdifffoundation.org/

November Is C. diff. Awareness Month

NEW PORT RICHEY, Fla. /ScoopCloud/ -- The C Diff Foundation reemphasizes that the month of November is "C. diff. awareness month" and is being recognized with its partners around the globe again in 2019.

Nancy Caralla, Founding President, Executive Director of the C Diff Foundation, and three-time C. diff. Survivor said, "The month of November was chosen for two reasons. On November 1, 2012 the C Diff Foundation came to fruition. Also, after suffering through the second newly diagnosed CDI with nine-recurrences over a year's time, the month of November was chosen because it was the first month that I received a negative CDI test result without further recurrences."

Caralla further explained that over the past seven years other organizations and survivors, with their families, have joined the C Diff Foundation in "Raising C. diff. Awareness," especially in the month of November originally coined by the C Diff Foundation worldwide.

At the 7th Annual International C. diff. Awareness Conference and Health EXPO held in St. Louis, Missouri on November 6-7, the conference program included Government Agency healthcare professionals and representatives who delivered presentations focused on, but not limited to, Clostridioides difficile. Global organization health care professionals in attendance also recognize November is C. diff. Awareness Month through their presentations, posters, and by introducing products and/or services preventing, treating, diagnosing a CDI and maintaining safer environments in the healthcare community.

C Diff Foundation expresses their gratitude to the numerous state Governors who have recognized C. diff. infections as a leading Healthcare-associated infection by raising awareness during the month of November in their respected states.

According to the Centers for Disease Control and Prevention (CDC), Clostridioides difficile infection (aka C. diff., C. difficile, CDI, CDAD) "has become the most common microbial cause of healthcare-associated infections in U.S. hospitals and costs up to $4.8 billion each year in excess health care costs for acute care facilities alone."

Statistics provided by the CDC suggest that C. difficile infections cause nearly 500,000 infections in patients in the U.S. annually. In one study noted by the CDC, among infected patients, nearly 29,000 died within 30 days of being diagnosed, and more than half of those deaths (15,000) were directly attributable to a C. difficile infection.

Learn more at: https://cdifffoundation.org/

About The C Diff Foundation:

C Diff Foundation, a 501(c)(3) established 2012, comprised of 100% volunteering professionals is dedicated at supporting public health through education and advocating for Clostridioides difficile infection (CDI) prevention, treatments, clinical trials, AMR, and environmental safety worldwide. Listen to "C.diff. Spores and More" Tuesdays at 1 p.m. EST (http://www.cdiffradio.com/), sponsored by Rebiotix, a Ferring Pharmaceuticals company.

Follow C Diff Foundation on LinkedIn, Twitter, Facebook, and Instagram. Twitter @cdiffFoundation #Cdiff2019

Media Contact:
Kathy Bischoff
C Diff Foundation
kathy@cdifffoundation.org
Office: (727) 205-3922

The C Diff Foundation reemphasizes that the month of November is "C. diff. awareness month" and is being recognized with its partners around the globe again in 2019.

Related link: https://cdifffoundation.org/

C Diff Foundation’s Junior Infection Fighters Program Takes Action against Harmful Germs One Community at a Time Worldwide

NEW PORT RICHEY, Fla. /ScoopCloud/ -- C Diff Foundation announced today that the inaugural C Diff Foundation Junior Infection Fighter Program was introduced to families and their children/teens in Chester County, Pennsylvania on October 12, 2019.

Dayle Skelly, Director of the Junior Infection Fighter Program and C. diff. Survivor said, "There shouldn't be an age limit for raising awareness of infection prevention. Children are our future and take forth the torch of knowledge to be shared with everyone in each community."

The volunteer program has been developed for children/teens with the participation and support of their parents/legal guardian and supervision of C Diff Foundation adult volunteers. C Diff Foundation's Junior Infection Fighters Program mission: "To educate and advocate for infection prevention with the children and teens and to inspire their social, academic, personal, and health care knowledge and partner with parents who share the same mission to prepare them to be members of ever changing global health care in societies worldwide."

C Diff Foundation's Junior Infection Fighter guidelines have been brought to fruition, under the direction of a leading infection preventionist, Maureen Spencer, RN, M.Ed., CIC.

Ms. Spencer who has been an Infection Preventionist for over 30 years and board certified in infection control (CIC). As one of the early pioneers in infection control, she was awarded the APIC National Carole DeMille Award in 1990 and was selected as one of the APIC Heroes of Infection Prevention in 2007 for her work in establishing a MRSA and Staph aureus Elimination Program at New England Baptist Hospital, an Orthopedic Center of Excellence in Boston. The ground breaking work was published in the Journal of Bone and Joint Surgery

All volunteer attendees enjoyed spending time learning more about practicing healthy habits combined with infection prevention information during the inaugural community event.

"We work together to carve new paths in the multi-faceted patient and family programs offered by C Diff Foundation. Together we build awareness and advocate for C. diff. infection prevention, treatments, clinical trials, antibiotic-resistance, and environmental safety worldwide. We are truly grateful to the dedicated members taking the C Diff Foundation's mission to greater levels changing lives, and saving lives across the globe," said Nancy C. Caralla, Founding President, C Diff Foundation.

About The C Diff Foundation:

C Diff Foundation, a 501(c)(3) established 2012, comprised of 100% volunteering professionals is dedicated at supporting public health through education and advocating for Clostridioides difficile infection (CDI) prevention, treatments, clinical trials, AMR, and environmental safety worldwide. Listen to "C.diff. Spores and More" Tuesdays at 1 p.m. ET (www.cdiffradio.com), sponsored by Rebiotix, a Ferring Pharmaceuticals company.

Learn more at: http://cdifffoundation.org

Follow C Diff Foundation on LinkedIn, Twitter, Facebook, and Instagram. Twitter @cdiffFoundation @Cdiff2019

Media Contact:
Dayle Skelly
Director Junior Infection Fighters Program
C Diff Foundation
info@cdifffoundation.org
Office: (727) 205-3922

*IMAGE link for media: https://www.Send2Press.com/300dpi/19-1015s2p-CdiffJuniorInfectionFighters-300dpi.jpg

###
Costs associated with dissemination of this news announcement were donated to the C Diff Foundation by NEOTROPE®, a California-based marketing company.

C Diff Foundation announced today that the inaugural C Diff Foundation Junior Infection Fighter Program was introduced to families and their children/teens in Chester County, Pennsylvania on October 12, 2019.

Related link: https://cdifffoundation.org/

C Diff Foundation Raises Clostridioides difficile Awareness in St. Louis on Nov. 6-7 at 7th Annual International Conference and Health EXPO

ST. LOUIS, Mo. /ScoopCloud/ -- C Diff Foundation announced today that the 7th Annual International C. diff. Conference and Health EXPO is honored to welcome over 30 international topic-experts dedicated in disciplines of healthcare, pharma, biotech, academia, and Government agencies.

Presenters will deliver data and discuss critical information on a leading Healthcare-Associated Infection (HAI), Clostridioides difficile with global healthcare-associated issues on November 6 - 7, 2019 at the DoubleTree by Hilton Westport Hotel, 1973 Craigshire Road, St. Louis, MO 63146; Telephone: +1 (314) 434-0100.

To learn more about this extraordinary conference, guest speakers, and the diverse topics being presented visit: https://cdifffoundation.org/2019-guest-speakers/

All attendees will have the highest levels of peer networking and learning opportunity at the Conference and Health EXPO.

C Diff Foundation expresses their gratitude to Pfizer for being the conference Diamond Sponsor. Pfizer is appreciated for their continued support and partnering with the C Diff Foundation in promoting C. diff. Awareness worldwide. This activity has been supported by an independent patient advocacy Grant from Merck & Co., Inc., and the members of the C Diff Foundation are truly grateful.

Attendee Paul Feuerstadt MD, FACG, AGAF stated, "The annual C Diff Foundation conference and health expo is an essential conference for me to attend, given the comprehensive presentations about epidemiology, disease state, patient experience, infection control and innovations with treatment of C. difficile. The level of detail and data presented has a wonderful balance that is understandable for someone casually interested in the infection but also exceeds the expectations for those who are experts in the field wanting to share and exchange ideas with other thought leaders."

According to the Centers for Disease Control and Prevention (CDC), Clostridioides difficile infection (aka C. diff., C. difficile, CDI, CDAD) "has become the most common microbial cause of healthcare-associated infections in U.S. hospitals and costs up to $4.8 billion each year in excess health care costs for acute care facilities alone."

Statistics provided by the CDC suggest that C. difficile infections cause nearly 500,000 infections in patients in the U.S. annually. In one study noted by the CDC, among infected patients, nearly 29,000 died within 30 days of being diagnosed, and more than half of those deaths (15,000) were directly attributable to a C. difficile infection.

About The C Diff Foundation:

C Diff Foundation, a 501(c)(3) established 2012, comprised of 100% volunteering professionals is dedicated at supporting public health through education and advocating for Clostridioides difficile infection (CDI) prevention, treatments, clinical trials, AMR, and environmental safety worldwide. Listen to "C.diff. Spores and More" Tuesday's at 1 p.m. EST (www.cdiffradio.com) sponsored by Rebiotix, a Ferring Pharmaceuticals company.

Learn more at: https://cdifffoundation.org/.

Follow C Diff Foundation on LinkedIn, Twitter, Facebook, and Instagram. Twitter @cdiffFoundation #Cdiff2019

Media Contact:
Angelo Ortiz
C Diff Foundation
angelo.ortiz@cdifffoundation.org
Office: (727) 205-3922

*IMAGE link for media: https://www.Send2Press.com/300dpi/19-1015s2p-cdiff-nov-expo-300dpi.jpg

C Diff Foundation announced today that the 7th Annual International C. diff. Conference and Health EXPO is honored to welcome over 30 international topic-experts dedicated in disciplines of healthcare, pharma, biotech, academia, and Government agencies. November 6 - 7, 2019 at the DoubleTree by Hilton Westport Hotel.

Related link: https://cdifffoundation.org/

C Diff Foundation with Leading Gastroenterologists Paul Feuerstadt, MD and Caterina Oneto, MD Announce Clinic Dedicated For C.difficile

HAMDEN, Conn. /ScoopCloud/ -- C Diff Foundation ( https://cdifffoundation.org/ ), a one hundred percent volunteer, world renowned 501(c)(3) not-for-profit organization announced today that the Foundation will offer the first ever clinic sponsored by the C Diff Foundation and dedicated to patients diagnosed and recovering from a C. difficile infection (CDI).

The clinic will hold office hours beginning this month in Connecticut, which will be held on August 27, 2019 at the Gastroenterology Center of Connecticut (gastrocenter.org).

The second clinic will be held in November (date to be announced) at the Concorde Medical Group in Manhattan - New York City (www.concordemed.com). The clinic received an overwhelming response from patients in various stages of recovery, including 15 individuals already scheduled with multiple spots planned for patients with recently diagnosed infection or those who have had multiple episodes and need further guidance and management.

"We are delighted with the immediate and overwhelming response from the patient community. It is a testament to the needs of those suffering from this infection. With this clinic we hope to bring awareness, education and more importantly, cutting edge treatment to the general public," stated Dr. Feuerstadt.

There are plans for additional clinic dates next year in New York, Connecticut, Illinois and Minnesota.

Dr. Oneto said, "Through this clinic, we will provide access to high level care to a number of new consults, as well as existing patients, who are recovering from the infection. It is my pleasure to partner with the C Diff Foundation and lend my expertise to the management and hopefully, eradication of this debilitating disease."

"The clinics demonstrate Dr's Feuerstadt and Oneto's commitment over the many years raising C.diff. awareness while providing management of those suffering with a C.diff. infection for patients who might not otherwise be able to gain access to providers sub-specializing in caring for those with this infection. Their dedication resonates within the C.diff. community and we are grateful for their participation and support." stated Nancy Caralla, Founding President of the C Diff Foundation.

About C Diff Foundation

C Diff Foundation's mission is dedicated to reaching out to communities from villages to cities, to medical practitioners, medical students, C. diff. survivors, caregivers, and the patients combating a C. difficile infection (CDI) while providing the general public important information on prevention, treatments available, clinical trials in progress, and EPA registered products available for environmental safety worldwide.

About Paul Feuerstadt, MD

His areas of interest Clostridioides difficile infection (CDI) and ischemic diseases of the gut and in these areas he has presented his research extensively, authored and co-authored many manuscripts, textbook chapters and online modules. Another passion of Dr. Feuerstadt's is teaching, frequently giving lectures locally, regionally and nationally. He holds a clinical appointment as an Assistant Clinical Professor of Medicine at the Yale University School of Medicine and is a full-time attending physician at the Gastroenterology Center of Connecticut seeing patients with a broad spectrum of clinical gastroenterological diseases.

Dr. Feuerstadt attended the Weill Medical College of Cornell University in Manhattan for medical school and completed his residency in internal medicine at New York Presbyterian Hospital/Weill Cornell. His clinical fellowship training was completed at Montefiore Medical Center in the Bronx, New York.

About Caterina Oneto, MD

Dr. Caterina Oneto, MD is a Gastroenterologist in private practice in New York and is affiliated with NYU Langone. She completed her Fellowship in Gastroenterology at Montefiore Medical Center, Albert Einstein College of Medicine. Dr Oneto is Co-Director of Clinical trials at Concorde Medical Group. Her main focus is Irritable Bowel Disease (IBD),

Clostridioides difficile infections (AKA C.diff., C.difficile, CDI) and Microbiome modification. Dr Oneto is also Co-Director of the C.diff. Community Global Support program offered by the C Diff Foundation. Dr Oneto appears regularly on Doctor Radio on Sirius Xm and C.diff. Spores and More Radio (cdiffradio.com).

About C.difficile

It is the most common Healthcare-associated infection affecting an estimated 450,000 people annually in the United States alone with ~28,000 deaths from complications of this infection. This infection accounts for ~16% of all healthcare associated infections.

In the USA: Nearly half a million Americans suffer from Clostridioides difficile (C. diff.) infections in a single year according to a study released February 25, 2015 by the Centers for Disease Control and Prevention CDC).

**Approximately 29,000 patients died within 30 days of the initial diagnosis of C. difficile. Of those, about 15,000 deaths were estimated to be directly attributable to C. difficile infections (CDI), making C. difficile a very important cause of infectious disease death in the United States alone. More than 80 percent of the deaths associated with C. difficile occurred among Americans aged 65 years or older. C. difficile causes an inflammation of the colon and deadly diarrhea.

Learn more about the C Diff Foundation at: https://cdifffoundation.org

The C Diff Foundation, a one hundred percent volunteer, world renowned 501(c)(3) not-for-profit organization announced today that the Foundation will offer the first ever clinic sponsored by the C Diff Foundation and dedicated to patients diagnosed and recovering from a C. difficile infection (CDI).

Related link: https://cdifffoundation.org/

C.diff. International Conference and Health EXPO Will Deliver Up-to-date Clostridioides difficile Data + More Nov. 6-7 In St. Louis

ST. LOUIS, Mo. /ScoopCloud/ -- The C Diff Foundation is honored to welcome 30+ international leading topic experts from hospitals, pharma, biotech, academia, and Government agencies to deliver and discuss critical information on global healthcare-associated issues.

To learn more about this extraordinary conference, agenda and guest speakers: https://cdifffoundation.org/2019-guest-speakers/

Clinical professionals will gather for two days to present up-to-date data to expand on the existing knowledge and raise awareness of the urgency focused on, but not limited to, Clostridioides difficile (formally known as Clostridium difficile) infection (CDI) Prevention, Treatments, Research, Diagnostics, Clinical trials, and Environmental Safety.

There will also be presentations exclusively concentrated on Infection prevention, Fecal microbiota restoration and transplants for adults, a Panel of C. diff. infection Survivors; a patient's perspective, Microbiome research, Scientific posters and poster presentations, Antibiotic stewardship, Antimicrobial resistance, and a Healthcare EXPO component.

All attendees will have the highest levels of peer networking and learning opportunity at the Conference and Health EXPO. The conference program builds in time for face-to-face interaction between attending executives, corporate representatives and industry experts exhibiting.

C Diff Foundation expresses their gratitude to Pfizer for being the conference Diamond Sponsor. Pfizer is appreciated for their continued support and partnering with the C Diff Foundation in promoting C. diff. Awareness worldwide.

Attendee Linda Davis, RN, Patient Triage Specialist, said about the 2018 conference, "It's an excellent opportunity to have the ability to network with fellow-healthcare professionals from around the world. Each conference I have attended presents the opportunity to acquire knowledge with like-minded professionals striving to make a difference in the health care community. Attendees obtain the most innovative cutting-edge research and developments fighting today's complex world of healthcare-associated infections."

According to the Centers for Disease Control and Prevention (CDC), Clostridioides difficile infection (aka C.diff., C. difficile, CDI, CDAD) "has become the most common microbial cause of healthcare-associated infections in U.S. hospitals and costs up to $4.8 billion each year in excess health care costs for acute care facilities alone." Statistics provided by the CDC suggest that C. difficile infections cause nearly 500,000 infections in patients in the U.S. annually. In one study noted by the CDC, among infected patients, nearly 29,000 died within 30 days of being diagnosed, and more than half of those deaths (15,000) were directly attributable to a C. difficile infection.

About The C Diff Foundation:

C Diff Foundation, a 501(c)(3) established 2012, comprised of 100% volunteering professionals dedicated at supporting public health through education and advocating for Clostridioides difficile infection (CDI) prevention, treatments, clinical trials, and environmental safety worldwide. Listen to "C.diff. Spores and More" Tuesdays at 1 p.m. ET (www.cdiffradio.com), sponsored by Rebiotix, a Ferring Pharmaceuticals company, providing leading up-to-date information on topics that are aligned and connect with their organization's mission and more.

Learn more: https://cdifffoundation.org/

Follow C Diff Foundation on LinkedIn, Facebook, and Instagram. Twitter @cdiffFoundation #Cdiff2019

Media Contact:
Angelo Ortiz
C Diff Foundation
angelo.ortiz@cdifffoundation.org
Office: (727) 205-3922

The C Diff Foundation is honored to welcome 30+ international leading topic experts from hospitals, pharma, biotech, academia, and Government agencies to deliver and discuss critical information on global healthcare-associated issues.

Related link: https://cdifffoundation.org/

World Renowned C Diff Foundation Announces First Ever Appointment of Paul Feuerstadt, M.D. as Director of Medical Education

NEW PORT RICHEY, Fla. /ScoopCloud/ -- C Diff Foundation, a one hundred percent volunteer, world renowned 501(c)(3) not-for-profit organization, has appointed nationally renowned Gastroenterologist, Dr. Paul Feuerstadt as its first Director of Medical Education.

Dr. Feuerstadt said, "It is my honor to accept this position. I have been involved with the C Diff Foundation over the last 4.5 years and I look forward to assisting in the continued growth of the organization and ensuring that forward progress, awareness and education increases under my tenure. I look forward to working with the board and volunteers to increase awareness and funding across the country and around the world to highlight this disease through in person events, social media, and in the press."

Dr. Feuerstadt has spent his career refining his practice and expertise in C. difficile. He is dedicated to educating the public through his work with this organization.

Additionally, he plans to offer free patient and provider education through the launch of his new educational website, https://www.everythingcdifficile.com/. The goal of the site is to provide education through short videos with relevant clinical information for educational purposes. The site provides concise 3-5 minute lectures covering core topics, recent publications and major conferences about C. difficile infection to educate both patients and providers.

Nancy C. Caralla, Founding President, C Diff Foundation, commented: "Dr. Feuerstadt is a pre-eminent doctor in this space. His dedication and donation of his time and energy to this worthy cause has helped so many patients to date. We look forward to his enhanced leadership and knowledge as the organization grows and strengthens through our advocacy in the C.diff. community. Dr. Feuerstadt's new role as Director of Medical Education will provide an additional avenue of support to patients, families, and caregivers through his educational media available on EverythingCdifficile.com. We are grateful for Dr. Feuerstadt's time and dedication as we continue fighting this debilitating disease worldwide."

About C Diff Foundation:

The C Diff Foundation's mission is dedicated to reaching out to communities from villages to cities, to medical practitioners, medical students, C. diff. survivors, caregivers, and the patients combating a C. difficile infection (CDI) while providing the general public important information on prevention, treatments available, clinical trials in progress, and EPA registered products available for environmental safety.

The C Diff Foundation continues moving forward setting up outreach centers and building positive networks with the C Diff Foundation Volunteer Health Advocates aiding in "Raising C.diff. Awareness" worldwide.

Learn more: https://cdifffoundation.org/

About Dr. Paul Feuerstadt:

His areas of interest Clostridioides difficile infection and ischemic diseases of the gut and in these areas he has presented his research extensively, authored and co-authored many manuscripts, textbook chapters and online modules. Another passion of Dr. Feuerstadt's is teaching, frequently giving lectures locally, regionally and nationally. He holds a clinical appointment as an Assistant Clinical Professor of Medicine at the Yale University School of Medicine and is a full time attending physician at the Gastroenterology Center of Connecticut seeing patients with a broad spectrum of clinical gastroenterological diseases.

Dr. Feuerstadt attended the Weill Medical College of Cornell University in Manhattan for medical school and completed his residency in internal medicine at New York Presbyterian Hospital/Weill Cornell. His clinical fellowship training was completed at Montefiore Medical Center in the Bronx, New York.

About C.difficile:

It is the most common Healthcare-associated infection affecting an estimated 450,000 people annually in the United States alone with ~28,000 deaths from complications of this infection. This infection accounts for ~16% of all healthcare associated infections.

In the USA: Nearly half a million Americans suffer from Clostridioides difficile (C. diff.) infections in a single year according to a study released February 25, 2015 by the Centers for Disease Control and Prevention CDC).

**Approximately 29,000 patients died within 30 days of the initial diagnosis of C. difficile. Of those, about 15,000 deaths were estimated to be directly attributable to C. difficile infections (CDI), making C. difficile a very important cause of infectious disease death in the United States alone. More than 80 percent of the deaths associated with C. difficile occurred among Americans aged 65 years or older. C. difficile causes an inflammation of the colon and deadly diarrhea.

C Diff Foundation, a one hundred percent volunteer, world renowned 501(c)(3) not-for-profit organization, has appointed nationally renowned Gastroenterologist, Dr. Paul Feuerstadt as its first Director of Medical Education.

Related link: https://cdifffoundation.org/

C Diff Foundation Hosts 3rd Annual Global C.diff. Awareness 2K Walks

TEANECK, N.J. /ScoopCloud/ -- C Diff Foundation announced today that registration is now open for the 3rd Annual Global C.diff. Awareness 2K Walks. The events, which will take place at the Morris A. Votee Park, Teaneck, N.J., Charlestown Township Park, Phoenixville, Pa., and Sims Park, New Port Richey, Fla., will be hosted by the C Diff Foundation on Saturday, May 18, 2019 from 8 a.m. - 12 p.m.

Dr. Martha Cloakie, PhD will be leading the walk in Leicester, U.K. on Friday, May 17, 2019.

All registered awareness walkers will receive t-shirts, giveaways, and educational material while introducing the communities to the resources available. C.diff. infections are one of the leading healthcare-associated infections facing local communities.

Registration is $20.00 per walker and children 10 years of age and under walk free. https://cdifffoundation.org/3rdannualwalk/

Proceeds from the events will benefit the C Diff Foundation's mission educating and advocating for C.difficile infection prevention, treatments, clinical trials, and environmental safety worldwide.

According to the Centers for Disease Control and Prevention (CDC), a Clostridioides difficile infection (C.difficile), (formally known as Clostridium difficile) "has become the most common microbial cause of healthcare-associated infections in U.S. hospitals and costs up to $4.8 billion each year in excess health care costs for acute care facilities alone."

Statistics provided by the CDC suggest that C. difficile cause nearly 500,000 infections in patients in the U.S. annually. In one study noted by the CDC, among infected patients, nearly 29,000 died within 30 days of being diagnosed, and more than half of those deaths (15,000) were directly attributable to a C. difficile infection.

"Every day the C Diff Foundation members work to educate and advocate for C. difficile infection prevention, treatments, clinical trials, and environmental safety while providing support worldwide. Our dedication to the cause is making a difference as we share a common goal with government agencies and health care organizations witnessing a decrease in newly diagnosed C.diff. infections and saving lives. Our dedicated volunteering members, around the globe, are focused on improving the lives of individuals and families who are impacted by C.diff. infections," says Nancy Caralla, Founding President, and Executive Director of the C Diff Foundation.

We sincerely thank Vedanta Biosciences, Inc. for being the Diamond Sponsor of the 3rd Annual Global C.diff. Awareness 2K Walks. Vedanta Biosciences, Inc. is dedicated to finding treatments for patients with serious infections and immune diseases. Vedanta develops medicines made of consortia of bacterial strains which are selected to effect robust and durable changes in a patient's gut microbiota.

In contrast to fecal transplants or administration of fecal fractions, Vedanta's medicines are pure, uniform compositions of bacteria manufactured from clonal cell banks, bypassing the need to rely on direct sourcing of fecal donor material of inconsistent composition. Vedanta is currently enrolling patients with recurrent C. difficile infections (CDI) in its CONSORTIUM study to evaluate VE303, an investigational treatment for CDI.

About the C Diff Foundation:

The C Diff Foundation, a 501(c)(3) supports public health through educating and advocating for C. difficile infection prevention, treatments, clinical trials, and environmental safety worldwide. For more information, or to find out how you can be a host of a Global C.diff. Awareness 2K Walk visit http://www.cdifffoundation.org.

Follow C Diff Foundation on Twitter
@cdiffFoundation
#CdiffWalk2019

The C Diff Foundation announced today that registration is now open for the 3rd Annual Global C.diff. Awareness 2K Walks. The events, which will take place at the Morris A. Votee Park, Teaneck, N.J., Charlestown Township Park, Phoenixville, Pa., and Sims Park, New Port Richey, Fla., will be hosted by the C Diff Foundation on Saturday, May 18, 2019 from 8 a.m. - 12 p.m.

Related link: https://cdifffoundation.org/

The C Diff Foundation Has Declared an Urgent Need to Raise Clostridium difficile Infection Clinical Trial Awareness Worldwide

TAMPA, Fla. /ScoopCloud/ -- The C Diff Foundation announced today that their organization has implemented a global campaign to raise awareness of Clostridioides difficile clinical trials, clinical studies, clinical research and observational studies evaluating interventions for C. difficile prevention, treatments, and environmental safety.

Clostridioides difficile is also known as C.difficile, C.diff, CDI (Clostridioides difficile infection), CDAD (Clostridioides difficile-associated disease) and formally called Clostridium difficile.

In the USA: Nearly half a million Americans suffer from Clostridioides difficile (C. diff.) infections in a single year according to a study released in 2015 by the Centers for Disease Control and Prevention (CDC). Approximately 29,000 patients died within 30 days of the initial diagnosis of C. difficile. About 15,000 deaths were estimated to be directly attributable to C. difficile infections making it a very important cause of infectious disease death in the United States.

"The broad range of new therapies for Clostridium difficile (C.difficile) is being intensely studied in several essential global clinical trials. This continued research underpins the current clinical needs with both preventing and treating C.difficile," stated Glenn S. Tillitson, Ph.D., FRSM, FCCP.

Individuals volunteer to participate in clinical trials in hopes of improving their own health, to access treatments that might not be available otherwise, often because they are new and not yet widely available. They help others by contributing to advances in medicine. There can also be potential risks participating in clinical trials and clinical studies. All of the known risks associated with a particular trial and or study will be discussed during the informed consent process. It will be thoroughly explained in the informed consent document that a volunteer will receive from the research staff prior to participating in any study.

To learn more about clinical research (e.g., Clostridioides difficile formally Clostridium difficile, also known as C.diff. C.difficile. CDI, CDAD) visit the U.S. Food and Drug Administration https://www.fda.gov/ or telephone 1-800-835-4709, and visit https://clinicaltrials.gov/.

"Clinical trials are vital to improving our knowledge about how best to prevent and treat C. difficile infections. Informing patients of clinical trials is important, and in recent years several clinical trials have led to significant improvements in the treatments available for patients with C. difficile infections. Clinical trials are a vital way of making progress in our search for new therapies to prevent and treat a CDI," stated Mark Wilcox, MD, FRCPath, Consultant Microbiologist, Head of Microbiology and Academic Lead of Pathology Leeds Teaching Hospitals, Professor of Medical Microbiology University of Leeds Institute of Biomedical and Clinical Sciences, Lead on Clostridium difficile for Public Health England, UK.

About the U.S. Food and Drug Administration (FDA):

The FDA is responsible for protecting the public health by assuring that foods are safe, wholesome, sanitary and properly labeled; ensuring that human and veterinary drug, and vaccines and other biological products and medical devices intended for human use are safe and effective. FDA's responsibilities extend to the 50 United States, the District of Columbia, Puerto Rico, Guam, the Virgin Islands, American Samoa, and other U.S. territories and possessions.

About ClinicalTrials.gov:

ClinicalTrials.gov is a Web-based resource that provides patients, their family members, health care professionals, researchers, and the public with easy access to information on publicly and privately supported clinical studies on a wide range of diseases and conditions.

About the C Diff Foundation:

The C Diff Foundation, a 501(c)(3) non-profit, founded in 2012 with a global mission of providing education for C.difficile infection prevention, treatments, environmental safety and support through research being conducted by the government, industry, and academia and provide better advocacy on behalf of patients, healthcare professionals, and researchers worldwide.

For information please visit http://www.cdifffoundation.org/.

The C Diff Foundation announced today that their organization has implemented a global campaign to raise awareness of Clostridioides difficile clinical trials, clinical studies, clinical research and observational studies evaluating interventions for C. difficile prevention, treatments, and environmental safety.

Related link: https://cdifffoundation.org/

C Diff Foundation Recognizes Rebiotix CEO with 2019 ‘Above and Beyond’ Award

NEW PORT RICHEY, Fla. /ScoopCloud/ -- The C. Diff Foundation Board of Directors announced today that the 2019 "Above and Beyond" Award will be presented to Rebiotix CEO Lee Jones in Roseville, Minnesota. The award, given to one recipient annually, is given to a person or organization that show extraordinary dedication to C. diff patient safety, advocacy, and overall drive to improve the lives of those impacted by the infection.

"We are very proud to recognize Ms. Jones with our "Above and Beyond" award," said C. Diff Foundation Founder and President, Nancy Caralla. "Lee's dedication to the entire C. diff community of patients, family members, and physicians hasn't wavered since the founding of Rebiotix in 2011. She is a true example of what can happen when focusing on patient well-being drives new approaches to healthcare."

The award will be presented by the Foundation's Vice President, Scott Battles, and Treasurer Angelo Ortiz at the Rebiotix facility.

"It's an honor to receive this award from the C. Diff Foundation," said Ms. Jones. "The purpose of starting Rebiotix was to bring the power of the microbiome to the clinic in a scientifically sound, quality-controlled way to help patients. We stand with the Foundation in believing that patient well-being should be at the core of all that we do, from clinical trials to exploring new scientific landscapes within the microbiome space."

About the C Diff Foundation:

The C Diff Foundation is a non-profit, 501(c)(3) organization established in 2012. It is comprised of 100% volunteering professionals dedicated to supporting public health through education and advocacy for C. difficile infection prevention, treatments, environmental safety and support world-wide. The Foundation's CEO and founder is a nurse inspired to create the foundation after witnessing the loss of her father to CDI, as well as suffering from the infection herself. The C Diff Foundation members, with their volunteer patient advocates, successfully "raise C. diff awareness" locally and in over fifty-six (56) countries and host a U.S. nation-wide hotline (1-844-FOR-CDIF) to support healthcare providers, patients and families through the difficulties of a C. diff infection. Learn more: https://cdifffoundation.org/

About Rebiotix Inc.:

Rebiotix Inc., part of the Ferring Pharmaceuticals Group, is a late-stage clinical microbiome company focused on harnessing the power of the human microbiome to revolutionize the treatment of debilitating diseases. Rebiotix possesses a deep and diverse clinical pipeline, with its lead drug candidate, RBX2660, in Phase 3 clinical development for the prevention of recurrent Clostridium difficile (C. diff) infection. RBX2660 has been granted Fast Track, Orphan and Breakthrough Therapy designation from the FDA for its potential to prevent recurrent C. diff infection.

Rebiotix's clinical pipeline also features RBX7455, a lyophilized, room temperature stable oral capsule formulation. Rebiotix is also targeting several other disease states with drug products built on its pioneering Microbiota Restoration Therapy(tm) platform. For more information on Rebiotix and its pipeline of human microbiome-directed therapies, visit https://www.rebiotix.com/

Twitter: @cdiffFoundation #CdiffInfection #Clostridiumdifficile @Rebiotix

The C. Diff Foundation Board of Directors announced today that the 2019 "Above and Beyond" Award will be presented to Rebiotix CEO Lee Jones in Roseville, Minnesota. The award, given to one recipient annually, is given to a person or organization that show extraordinary dedication to C. diff patient safety, advocacy, and overall drive to improve the lives of those impacted by the infection.

Related link: https://cdifffoundation.org/

Leading Companies to Support C Diff Foundation 6th Annual International C.diff. Conference and Health EXPO, Nov. 8-9, Philadelphia

PHILADELPHIA, Pa. /ScoopCloud/ -- The C Diff Foundation is honored to welcome leading companies to the 6th Annual International "C.diff. Awareness Conference and Health EXPO," as they come together to make a global difference. These companies are dedicated to the prevention, diagnostics, treatments, environmental safety products and services focused on C.difficile infections and Healthcare-associated infections and whose role serves great importance in the C.diff. community.

The conference takes place on November 8 and 9, 2018 at the Embassy Suites by Hilton Philadelphia Airport Hotel, Philadelphia, Pennsylvania.

"We at Synthetic Biologics are thrilled to partner with the C Diff Foundation in their fight to increase research partnerships, education and advocacy of awareness of Clostridium difficile Infection," said Deb Mathews, PharmD, Vice President, Medical Affairs of Synthetic Biologics. "This conference consistently brings the highest caliber of speakers, rigorously sound clinical data, an impassionate approach and an unyielding commitment in the fight against the incredible unmet medical needs for patients inflicted with and affected by Clostridium difficile Infection."

According to the Centers for Disease Control and Prevention (CDC), Clostridium difficile infection "has become the most common microbial cause of healthcare-associated infections in U.S. hospitals and costs up to $4.8 billion each year in excess health care costs for acute care facilities alone." Statistics provided by the CDC suggest that C. difficile cause nearly 500,000 infections in patients in the U.S. annually and 14,000 deaths a year directly related to this infection.

The 6th Annual International C. diff. Conference & Health EXPO brings together C. diff survivors, physicians, researchers and industry members focused on reducing the major burden of C. difficile infection on global healthcare systems.

"We're privileged to be able to present alongside distinguished C. difficile infection experts and to share with the community our progress on advancing our Phase 3-ready precision antibiotic ridinilazole as a potential new front-line treatment option for patients with C. difficile infection," said Dr. David Roblin, President of R&D of Summit Therapeutics.

With upmost appreciation we thank the following Sponsors for their continued support and partnering with the C Diff Foundation promoting C. diff. awareness worldwide:
- Diamond: Synthetic Biologics.
- Gold: Clorox Healthcare, Seres Therapeutics, ROCHE, Rebiotix, Pfizer.
- Silver: CutisPharma, TechLab, Tru-D Smart UVC, Summit Therapeutics.
- Bronze: Honey Bee Handiworks, Qmetis, Seal Shield, Trinity Guardion, Steriliz RD Rapid UVC, Safety Net America, SporeGen.
- Luncheon: Finch Therapeutics, Synexsis.
- A/V - DaVolterra.

This conference is supported through an educational grant from Sanofi Pasteur US. This activity has been supported by an independent patient advocacy grant from Merck & Co., Inc.

About The C Diff Foundation:

The C Diff Foundation, a 501(c)(3) established 2012, comprised of 100% volunteering professionals dedicated at supporting public health through education and advocating for C. difficile infection (CDI) prevention, treatments, clinical trials, environmental safety, and support worldwide. https://cdifffoundation.org/.

Follow C Diff Foundation on Facebook, Instagram.

Twitter @cdiffFoundation #Cdiff2018

The C Diff Foundation is honored to welcome leading companies to the 6th Annual International "C.diff. Awareness Conference and Health EXPO," as they come together to make a global difference. These companies are dedicated to the prevention, diagnostics, treatments, environmental safety products and services focused on C.difficile infections and Healthcare-associated infections and whose role serves great importance in the C.diff. community.

Related link: https://cdifffoundation.org/

6th Annual International C.diff. Conference and Health EXPO in Philadelphia PA November 8-9

PHILADELPHIA, Pa. /ScoopCloud/ -- The C Diff Foundation is honored to welcome 20+ leading topic experts joined by Dale Gerding, MD, FACP, FIDSA, Professor of Medicine at Loyola University Chicago Stritch School of Medicine in Maywood, Illinois and Research Physician at the Edward Hines Jr. VA Hospital and Mark Wilcox,B Med Sci, BM, BS, MD, FRCPath-, Head of Microbiology and Academic Lead of Pathology at the Leeds Teaching Hospitals (LTHT), Professor of Medical Microbiology at the University of Leeds, and Lead on Clostridium difficile for Public Health England (PHE).

Dale Gerding, MD, FACP, FIDSA and Mark Wilcox, B Med Sci, BM ,BS, MD, FRCPath- will be this year's Conference Chairs of the upcoming 6th Annual International "C.diff. Awareness Conference and Health EXPO," taking place on November 8 and 9, 2018 at the Embassy Suites by Hilton Philadelphia Airport - Philadelphia, Pennsylvania.

Dale Gerding, MD, FACP, FIDSA and Mark Wilcox,B Med Sci, BM, BS, MD, FRCPath- join the internationally recognized experts in health care, academic, and industry leaders to discuss the burden of Clostridium difficile infections (C.difficile, C.diff., CDI) Prevention, Treatments, Diagnostics, Research, Clinical Trials, with Microbiome Research, Infection Prevention, Sepsis Prevention, Environmental Safety, Fecal Microbiota Restoration, Antibiotic Stewardship, Scientific Poster Presentations and more.

To learn more about this extraordinary conference, agenda and guest speakers: https://cdifffoundation.org/2018-guest-speakers/

According to the Centers for Disease Control and Prevention (CDC), Clostridium difficile infection (C. difficile) "has become the most common microbial cause of healthcare-associated infections in U.S. hospitals and costs up to $4.8 billion each year in excess health care costs for acute care facilities alone." Statistics provided by the CDC suggest that C. difficile cause nearly 500,000 infections in patients in the U.S. annually. In one study noted by the CDC, among infected patients, nearly 29,000 died within 30 days of being diagnosed, and more than half of those deaths (15,000) were directly attributable to a C. difficile infection.

All attendees will have the highest levels of peer networking and learning opportunity at the International C.diff. Awareness Conference and Health EXPO. The conference program builds in time for face-to-face interaction between attending executives, corporate representatives and industry experts exhibiting in the health expo.

Attendee Barley Chironda, Infection Control Specialist, said about the 2017 conference, "I have attended all of the C Diff Foundation Conferences and I am always in awe at the wealth of new information that is presented at each conference. As an Infection Control Specialist, and a person who deals with Healthcare Infections, I feel this conference allows great knowledge sharing and networking."

With upmost appreciation we thank the following Exhibiting Sponsors for their continued support and partnering with the C Diff Foundation in promoting C. diff. Awareness worldwide:
- Diamond: Synthetic Biologics.
- Gold: Clorox Healthcare, Seres Therapeutics, ROCHE, Rebiotix, Pfizer.
- Silver: Mr. & Mrs. Angelo Ortiz.
- Bronze: Honey Bee Handiworks, Trinity Guardion, Steriliz, Safety Net America, SporeGen.

This conference is supported through an educational grant from Sanofi Pasteur US.

Visit https://cdifffoundation.org for more information. Contact Angelo Ortiz for registration, exhibiting/sponsor opportunities, and media partnerships: angelo.ortiz@cdifffoundation.org or Mobile (919) 201-1512.

About The C Diff Foundation:

The C Diff Foundation, a 501(c)(3) established 2012, comprised of 100% volunteering professionals dedicated at supporting public health through education and advocating for C. difficile infection (CDI) prevention, treatments, environmental safety, and support worldwide. Listen to "C.diff. Spores and More" Tuesday's at 1 p.m. ET (www.cdiffradio.com), sponsored by Clorox Healthcare, providing leading up-to-date information on topics that are in align with their mission.

Follow C Diff Foundation on LinkedIn, Facebook, and Instagram. Twitter @cdiffFoundation #Cdiff2018

The C Diff Foundation is honored to welcome 20+ leading topic experts joined by Dale Gerding, MD, FACP, FIDSA, Professor of Medicine at Loyola University Chicago Stritch School of Medicine in Maywood, Illinois and Research Physician at the Edward Hines Jr. VA Hospital and Mark Wilcox, B Med Sci, BM, BS, MD, FRCPath-, Head of Microbiology and Academic Lead of Pathology at the Leeds Teaching Hospitals (LTHT).

Related link: https://cdifffoundation.org/

2nd Annual Global C.diff. Walks in US and UK to Raise Awareness on Importance of Clostridium difficile Infections Worldwide

TEANECK, N.J. /ScoopCloud/ -- Presented by the C Diff Foundation, the 2nd Annual Global C.diff. Awareness 2K Walks will take place on Saturday, May 19 at three separate locations: Morris A. Votee Park, Teaneck, New Jersey; Sims Park, New Port Richey, Florida; and in Leicester, England. All locations will include t-shirts and resourceful educational material for all registered walkers. The U.S. locations will also include water bottles and hydration stations.

According to the Centers for Disease Control and Prevention (CDC), Clostridium difficile infection (C. difficile) "has become the most common microbial cause of healthcare-associated infections in U.S. hospitals and costs up to $4.8 billion each year in excess health care costs for acute care facilities alone." Statistics provided by the CDC suggest that C. difficile cause nearly 500,000 infections in patients in the U.S. annually. In one study noted by the CDC, among infected patients, nearly 29,000 died within 30 days of being diagnosed, and more than half of those deaths (15,000) were directly attributable to a C. difficile infection.

The Global C. diff. Walks will raise awareness of

Clostridium difficile (C. diff.) infection prevention and provide educational material while introducing the communities to the resources available. C.diff. infections are one of the leading health issues facing local communities.

"Every day the C Diff Foundation works to educate and advocate for C. difficile infection prevention, treatments, environmental safety and support worldwide to save lives. Our dedicated volunteering members are focused on improving the lives of individuals and families that are impacted by a C.diff. infection," says Nancy Caralla, Founding President of the C Diff Foundation.

We sincerely thank the following Sponsors for their continued support and for joining the C Diff Foundation in promoting
C. diff. Awareness worldwide:
Platinum: CutisPharma, Inc.
Gold: Pfizer and Xenex Disinfection Services.
Silver: Quellthera.

Event Details:
When: Saturday, May 19, 2018 - "rain or shine."

Registration and Check-in takes place at 8 a.m. Walk and Program begins at 9 a.m. at: Milton A. Votee Park, Queen Anne Rd & Court St, Teaneck, NJ 07666; Sims Park, 6341 Bank Street, New Port Richey, FL 34652; and being led by Dr. Martha Cloakie, PhD, a walk in the park in Leicester, England.

To register on-line: https://cdifffoundation.org/ or https://cdifffoundation.org/2nd-annual-global-walks-2018/

Walkers can register individually ($20 per person) or as a team ($20 for team leader) and teams can recruit sponsors.

All proceeds raised will support the program of the C Diff Foundation which provides villages to cities with C. difficile infection education, advocacy, and support worldwide.

For additional information about the walk, please email info@cdifffoundation.org or call the main office in U.S.: (919) 201-1512.

About the C Diff Foundation:

The C Diff Foundation, a 501(c)(3) established 2012, comprised of 100 percent volunteering professionals who are dedicated supporting public health through education and advocating for C. difficile infection (CDI) prevention, treatments, environmental safety, and support worldwide.

Follow C Diff Foundation on Twitter
@cdiffFoundation
#CdiffWalk2018

Media Contact:
Angelo Ortiz, Global Walk Committee
angelo.ortiz@cdifffoundation.org

Presented by the C Diff Foundation, the 2nd Annual Global C.diff. Awareness 2K Walks will take place on Saturday, May 19 at three separate locations: Morris A. Votee Park, Teaneck, New Jersey; Sims Park, New Port Richey, Florida; and in Leicester, England. All locations will include t-shirts and resourceful educational material for all registered walkers. The U.S. locations will also include water bottles and hydration stations.

Related link: https://cdifffoundation.org/

C Diff Foundation Presents Award to CutisPharma in Recognition of Contribution to C. diff. Community

NEW PORT RICHEY, Fla. /ScoopCloud/ -- The C Diff Foundation announced today that it presented CutisPharma, Inc., its "Making a Difference" award as a special recognition of the significant contribution that CutisPharma has made to the C.diff. Community: helping the advancement of C.diff. awareness as well as expanding treatment options for C.diff. patients.

The award was presented at CutisPharma's celebration of its upcoming launch of FIRVANQ(TM), recently approved by the FDA for the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains. Upon launch, FIRVANQ(TM) will be the only FDA-approved oral vancomycin solution treatment commercially available, improving patient access and reducing pharmacist burden by no longer having to compound oral liquid formulations.

"CutisPharma has been a committed partner of our Foundation and has furthered our mission to increase C.diff. awareness and support the research and development of new treatment options," said Nancy C. Caralla, Foundress and Executive Director of the C Diff Foundation. "In recognition of CutisPharma's efforts, we are pleased to grant them the 'Making a Difference' award at this special moment in the Company's 20th anniversary year."

"We are very grateful to receive such a special distinction from the C Diff Foundation," said Neal I. Muni, MD, MSPH, and Chief Executive Officer of CutisPharma. "For 20 years, we have been committed to improving the lives of patients who are not well-served by existing therapies and would benefit from high-quality, cost-effective new treatment options. We greatly value our partnership with the C Diff Foundation and look forward to continuing to support their mission."

In the USA: Nearly half a million Americans suffer from Clostridium difficile (C. diff.) infections in a single year according to a study released in 2015 by the Centers for Disease Control and Prevention (CDC). Approximately 29,000 patients died within 30 days of the initial diagnosis of C. difficile. Of those, about 15,000 deaths were estimated to be directly attributable to C. difficile infections making C. difficile a very important cause of infectious disease death in the United States.

About the C Diff Foundation:

The C Diff Foundation, a 501(c)(3)non-profit organization, established in 2012, is comprised of 100 percent volunteering professionals dedicated to supporting public health initiatives for C. difficile infection prevention, treatments, environmental safety, and support worldwide. For more information, visit: https://cdifffoundation.org/.

About CutisPharma:

CutisPharma, Inc., based in Wilmington, Mass., is privately held, specialty pharmaceutical company that has been the industry leader for 20 years in providing innovative solutions to pharmacists. CutisPharma's FIRST(r) Unit-of-Use Compounding Kits have benefited millions of patients who are unable to swallow conventional oral dosage forms such as tablets and capsules and whose needs are not served by commercially available therapies. The Company's first FDA-approved Kit, FIRVANQ(TM), will allow significantly broader patient access, convenience to pharmacists and patients alike by reducing the need for compounding, and serve as a potential cost-saving option to existing treatments. For more information, visit: https://cutispharma.com/.

The C Diff Foundation today announced that it presented CutisPharma, Inc., its "Making a Difference" award as a special recognition of the significant contribution that CutisPharma has made to the C.diff. Community: helping the advancement of C.diff. awareness as well as expanding treatment options for C.diff. patients.

Related link: https://cdifffoundation.org/

The C Diff Foundation Raises Clostridium difficile Infection (C.difficile) Clinical Trial Awareness Worldwide

TAMPA, Fla. /ScoopCloud/ -- The C Diff Foundation announced today that their organization has implemented a global campaign to raise awareness of Clostridium difficile infection (C.difficile) clinical trials, clinical studies, clinical research and observational studies evaluating interventions for C. difficile prevention, treatments, and environmental safety.

In the USA: Nearly half a million Americans suffer from Clostridium difficile (C. diff.) infections in a single year according to a study released in 2015 by the Centers for Disease Control and Prevention (CDC). Approximately 29,000 patients died within 30 days of the initial diagnosis of C. difficile. Of those, about 15,000 deaths were estimated to be directly attributable to C. difficile infections making C. difficile a very important cause of infectious disease death in the United States.

"Clostridium difficile infections are not only the most common cause of healthcare-acquired infections in the United States but also very common in the community in younger patients who previously were thought to be less susceptible to C. difficile. The rate of recurrent C. difficile infections is increasing tremendously and this increase is higher than the rate of primary C. difficile infections," stated Sahil Khanna, MD, Assistant Professor of Medicine Division of Gastroenterology and Hepatology, Director of the C. difficile Clinic, Fecal Microbiota Transplantation program and C. difficile related Clinical Trials, Mayo Clinic, Rochester, MN.

Dr. Khanna also added, "It is imperative and important for clinical trials to be done to advance the development of new treatments, new medications, and new ways to prevent and treat Clostridium difficile infections."

Individuals volunteer to participate in clinical trials in hopes of improving their own health, to access treatments that might not be available otherwise, often because they are new and not yet widely available. They help others by contributing to advances in medicine. There can also be potential risks participating in clinical trials and clinical studies. All of the known risks associated with a particular trial and or study will be discussed during the informed consent process. It will be thoroughly explained in the informed consent document that a volunteer will receive from the research staff prior to participating in any study.

To learn more about clinical research (e.g., Clostridium difficile, C.difficile) visit the U.S. Food and Drug Administration www.fda.gov or telephone 1-800-835-4709, The National Institutes of Health (NIH) www.nih.gov and ClinicalTrials.gov.

"Clinical trials are vital to improving our knowledge about how best to prevent and treat C. difficile infections. Informing patients of clinical trials is important, and in recent years several clinical trials have led to significant improvements in the treatments available for patients with C. difficile infections," stated Mark Wilcox, MD, FRCPath, Consultant Microbiologist, Head of Microbiology and Academic Lead of Pathology Leeds Teaching Hospitals, Professor of Medical Microbiology University of Leeds Institute of Biomedical and Clinical Sciences, Lead on Clostridium difficile for Public Health England, UK.

About the U.S. Food and Drug Administration (FDA):
The FDA is responsible for protecting the public health by assuring that foods are safe, wholesome, sanitary and properly labeled; ensuring that human and veterinary drug, and vaccines and other biological products and medical devices intended for human use are safe and effective. FDA's responsibilities extend to the 50 United States, the District of Columbia, Puerto Rico, Guam, the Virgin Islands, American Samoa, and other U.S. territories and possessions.

About the National Institutes of Health (NIH):
The National Institutes of Health (NIH), a part of the U.S. Department of Health and Human Services, is the nation's medical research agency making important discoveries that improve health and save lives.

About ClinicalTrials.gov
ClinicalTrials.gov is a Web-based resource that provides patients, their family members, health care professionals, researchers, and the public with easy access to information on publicly and privately supported clinical studies on a wide range of diseases and conditions.

About the C Diff Foundation:
The C Diff Foundation, a 501(c)3 non-profit, founded in 2012 with a global mission of providing education for Clostridium difficile infection prevention, treatments, environmental safety and support through research being conducted by the government, industry, and academia and provide better advocacy on behalf of patients, healthcare professionals, and researchers worldwide.

For information please visit https://cdifffoundation.org/.

The C Diff Foundation announced today that their organization has implemented a global campaign to raise awareness in 2018 of Clostridium difficile infection (C.difficile) clinical trials, clinical studies, clinical research and observational studies evaluating interventions for C. difficile prevention, treatments, and environmental safety.

Related link: https://cdifffoundation.org/

C Diff Foundation Introduces Book, ‘Nutrition – Managing Meals through a C. difficile Infection’

TAMPA, Fla. /ScoopCloud/ -- The C Diff Foundation announces the release of a nutritional guide, "Nutrition; Managing Meals through a C. difficile Infection" (ISBN: 978-1973304241) authored by Nancy C. Caralla, C Diff Foundation's Foundress, Executive Director and three time C. difficile Infection Survivor and co-author Karen F. Factor, MBA, RDN,CSR, LDN, C Diff Foundation Registered Dietitian during November 2017 Clostridium difficile (C. difficile, C.diff.) Infection Awareness Month.

According to the Centers for Disease Control and Prevention (CDC), Clostridium difficile infection (C. difficile) "has become the most common microbial cause of healthcare-associated infections in U.S. hospitals and costs up to $4.8 billion each year in excess health care costs for acute care facilities alone." Statistics provided by the CDC suggest that C. difficile cause nearly 500,000 infections in patients in the U.S. annually. In one study noted by the CDC, among infected patients, nearly 29,000 died within 30 days of being diagnosed, and more than half of those deaths (15,000) were directly attributable to a C. difficile infection.

The book is a useful tool for patients, caregivers and clinicians to inform, educate, and guide in the nutritional challenges that can occur during and after a C. difficile infection. The importance of proper nutrition is paramount in aiding individuals diagnosed and suffering with a C. difficile infection.

Paperback and Kindle Edition available through Amazon (http://a.co/iDBSedO) and the Book Patch.

"A Clostridium difficile infection impacts each person differently. Individuals will not all experience the same nutritional and hydration challenges. This book contains educational information centered on C. difficile infection prevention, nutrition, hydration, with chapters defining probiotics, Vitamin D, and environmental safety," stated Caralla.

Fifty percent of the income generated from the sales of "Nutrition; Managing Meals through a C. difficile Infection" will be donated to the C Diff Foundation to support and grow their mission -- Educating and advocating for C. difficile infection prevention, treatments, environmental safety, and support worldwide.

"Had this information been available at the initial diagnosis of this horrific infection the devastation and dietary complications would have been avoided. This information is invaluable to patients, their families and caregivers by providing the necessary tools to manage nutrition and hydration through a C. difficile infection," stated Kathy Bischoff, C. difficile infection survivor.

About the C Diff Foundation:
The C Diff Foundation, a 501(c)(3) established 2012, comprised of 100 percent volunteering professionals dedicated at supporting public health through education and advocating for C. difficile infection (CDI) prevention, treatments, environmental safety, and support worldwide. Visit https://cdifffoundation.org/.

Media Contact:
Denise Graham
denise@cdifffoundation.org.
Mobile: (919) 201-1512

*PHOTO for Media: Send2Press.com/300dpi/17-1130s2p-cdiff-nutrition-300dpi.jpg

The C Diff Foundation announces a new nutritional guide, "Nutrition; Managing Meals through a C. difficile Infection" (ISBN: 978-1973304241) authored by Nancy C. Caralla, C Diff Foundation's Foundress, Executive Director and three time C. difficile Infection Survivor and co-author Karen F. Factor, MBA, RDN,CSR, LDN, C Diff Foundation Registered Dietitian during November 2017 Clostridium difficile Infection Awareness Month.

Related link: https://cdifffoundation.org/

U.S. Governors Are Applauded for Proclaiming November Clostridium difficile (C.difficile, C.diff.) Infection Awareness Month

BALTIMORE, Md. /ScoopCloud/ -- Many U.S. Governors have signed a state proclamation proclaiming November 2017 as Clostridium difficile (C.difficile, C.diff.) Infection Awareness Month, the non-profit C Diff Foundation announced today.

According to the Centers for Disease Control and Prevention (CDC), Clostridium difficile infection (C. difficile) "has become the most common microbial cause of healthcare-associated infections in U.S. hospitals and costs up to $4.8 billion each year in excess health care costs for acute care facilities alone." Statistics provided by the CDC suggest that C. difficile cause nearly 500,000 infections in patients in the U.S. annually.

In one study noted by the CDC, among infected patients, nearly 29,000 died within 30 days of being diagnosed, and more than half of those deaths (15,000) were directly attributable to a C. difficile infection.

As a leading health care and patient advocacy organization the C Diff Foundation provides resources concerning C. difficile infection prevention, treatments, environmental safety, and support worldwide.

The C Diff Foundation continues to heighten the urgency of this life-threatening infection with government agencies, academia topic experts, and health care professionals worldwide.

"Our shared goal is to witness a significant reduction in C. difficile infections worldwide by the year 2020. We would also like to thank Rebiotix for their efforts and support with this endeavor," stated Nancy C. Caralla, Executive Director of the C Diff Foundation.

Through the State Proclamations Clostridium difficile (C.difficile, C.diff.) infection awareness has risen significantly worldwide.

About the C Diff Foundation:
The C Diff Foundation, a 501(c)(3) established 2012, comprised of 100-percent volunteering professionals dedicated at supporting public health through education and advocating for C. difficile infection (CDI) prevention, treatments, environmental safety, and support worldwide. Visit https://cdifffoundation.org/.

MEDIA CONTACT:
Denise Graham
telephone: 919-201-1512
denise@cdifffoundation.org

Many U.S. Governors have signed a state proclamation proclaiming November 2017 as Clostridium difficile (C.difficile, C.diff.) Infection Awareness Month, the non-profit C Diff Foundation announced today.

Related link: https://cdifffoundation.org/

Inaugural Global C. diff. Walk to raise awareness on importance of Clostridium difficile infection prevention and provide resources

NEW PORT RICHEY, Fla. /ScoopCloud/ -- Presented by the C Diff Foundation, the 1st Annual Global C.diff. Awareness 2K Walk will take place on Saturday, November 4 at Frances Park, New Port Richey, Florida. This event will include refreshments, hydration stations, and resourceful educational material and displays.

According to the Centers for Disease Control and Prevention (CDC), Clostridium difficile infection (C. difficile) "has become the most common microbial cause of healthcare-associated infections in U.S. hospitals and costs up to $4.8 billion each year in excess health care costs for acute care facilities alone." Statistics provided by the CDC suggest that C. difficile cause nearly 500,000 infections in patients in the U.S. annually. In one study noted by the CDC, among infected patients, nearly 29,000 died within 30 days of being diagnosed, and more than half of those deaths (15,000) were directly attributable to a C. difficile infection.

The Global C. diff. Walk seeks to raise awareness of Clostridium difficile (C. diff.) infection prevention and provide educational material while introducing the community to the resources available. C.diff. infections are one of the leading health issues facing local communities.

"Every day the C Diff Foundation works to educate and advocate for C. difficile infection prevention, treatments, environmental safety and support worldwide to save lives. Our dedicated volunteering members and patient advocates work to improve the lives of individuals and families that are impacted by a C.diff. infection," says Nancy Caralla, Board President of the C Diff Foundation.

We sincerely thank the following Sponsor for their continued support and for joining the C Diff Foundation in promoting C. diff. Awareness worldwide: Diamond: Seres Therapeutics.

Event Details:
Saturday, November 4, 2017. Registration and Check-in takes place at 8 a.m. Walk and Program begins at 9 a.m. at Frances Park, 5580 Frances Avenue, New Port Richey, Florida 34653.

Registration: https://cdifffoundation.org/.

Walkers can register individually ($5 per person) or as a team ($15 per team) and can recruit sponsors.

All funds raised will support the work of the C Diff Foundation that provide villages to cities with C. difficile infection education, advocacy, and support worldwide.

For additional information about the walk, email info@cdifffoundation.org or call (919)-201-1512.

About the C Diff Foundation:

The C Diff Foundation, a 501(c)(3) established 2012, comprised of 100% volunteering professionals dedicated at supporting public health through education and advocating for C. difficile infection (CDI) prevention, treatments, environmental safety, and support worldwide.

Follow C Diff Foundation on Twitter
@cdiffFoundation
#Cdiff2017

*IMAGE: Send2Press.com/300dpi/17-1003s2p-cdiff2k-flier-300dpi.jpg

Presented by the C Diff Foundation, the 1st Annual Global C.diff. Awareness 2K Walk will take place on Saturday, November 4 at Frances Park, New Port Richey, Florida. This event will include refreshments, hydration stations, and resourceful educational material and displays.

Related link: https://cdifffoundation.org/

C Diff Foundation Knocks on Governor’s Doors Nationwide to Proclaim the Month of November for Clostridium difficile Infection Awareness

NEW PORT RICHEY, Fla. /ScoopCloud/ -- C Diff Foundation welcomes November as Clostridium difficile Awareness Month and it is an exciting time for patients, families, clinicians, and organizations. Governors in several states honor our efforts by signing proclamations declaring November to be Clostridium difficile Awareness Month in their states.

These proclamations are available to you and can be downloaded for your use from our website: https://cdifffoundation.org/make-a-difference-november/.

This year, our goal is to obtain proclamations in all 50 states. Denise Graham, Strategic Advisor of the C Diff Foundation, proudly leads the Clostridium difficile (C. diff., C. difficile) State Proclamation effort.

Join us at the upcoming 5th Annual International C.diff. Awareness Conference and Health EXPO, taking place on November 9 and 10, 2017 at the University of Nevada - Las Vegas, Thomas and Mack Center, 2nd Floor Pavilion, Las Vegas, Nevada.

Complimentary registrations are available: https://cdifffoundation.org/registration/

According to the Centers for Disease Control and Prevention (CDC), Clostridium difficile infection (C. difficile) "has become the most common microbial cause of healthcare-associated infections in U.S. hospitals and costs up to $4.8 billion each year in excess health care costs for acute care facilities alone." Statistics provided by the CDC suggest that C. difficile cause nearly 500,000 infections in patients in the U.S. annually. In one study noted by the CDC, among infected patients, nearly 29,000 died within 30 days of being diagnosed, and more than half of those deaths (15,000) were directly attributable to a C. difficile infection.

Dale Gerding, MD, FACP, FIDSA joins 25+ internationally recognized experts in health care, academic, and industry leaders to discuss the burden of Clostridium difficile infections (C.difficile, C.diff., CDI) and prevention, treatments, diagnostics, research, clinical trials, with Microbiome research, Infection Prevention, Irritable Bowel Syndrome treatments and clinical trials, Environmental Safety, Fecal Microbiota Restoration, Antibiotic Stewardship and more.

To learn more about the program and guest speakers: https://cdifffoundation.org/cdiff2017guest-speakers/

Attendee Linda Jablonski, RN, BSN said about the 2016 conference, "The information shared at the conference provided up-to-date studies and important information that help us all save lives."

Visit https://cdifffoundation.org for more information. Contact Denise Graham for registration and media inquiries desinse@cdifffoundation.org or Mobile (202)-294-6314.

About the C Diff Foundation:
The C Diff Foundation, a 501(c)(3) established 2012, comprised of 100% volunteering professionals dedicated at supporting public health through education and advocating for C. difficile infection (CDI) prevention, treatments, environmental safety, and support worldwide.

Follow C Diff Foundation on Twitter
@cdiffFoundation
#Cdiff2017

Media Contact:
Denise Graham
denise@cdifffoundation.org

*IMAGE for media: Send2Press.com/300dpi/17-0928s2p-cdiff-awareness-300dpi.jpg

C Diff Foundation welcomes November as Clostridium difficile Awareness Month and it is an exciting time for patients, families, clinicians, and organizations. Governors in several states honor our efforts by signing proclamations declaring November to be Clostridium difficile Awareness Month in their states.

Related link: https://cdifffoundation.org/

Critical Healthcare-acquired Infections Expo comes to Las Vegas to Address C.difficile Concerns and Patient Risks

LAS VEGAS, Nev. /ScoopCloud/ -- LAS VEGAS, Nev., Aug. 16, 2017 (SEND2PRESS NEWSWIRE) -- C Diff Foundation welcomes Dale Gerding, MD, FACP, FIDSA, and Professor of Medicine at Loyola University Chicago Stritch School of Medicine in Maywood, Illinois and Research Physician at the Edward Hines Jr. VA Hospital as Conference Chair of the upcoming 5th Annual International "C.diff. Awareness Conference and Health EXPO," taking place on November 9 and 10, 2017 at the University of Nevada - Las Vegas, Thomas and Mack Center, 2nd Floor Pavilion.

According to the Centers for Disease Control and Prevention (CDC), Clostridium difficile infection (C. difficile) "has become the most common microbial cause of healthcare-associated infections in U.S. hospitals and costs up to $4.8 billion each year in excess health care costs for acute care facilities alone."

Statistics provided by the CDC suggest that C. difficile cause nearly 500,000 infections in patients in the U.S. annually. In one study noted by the CDC, among infected patients, nearly 29,000 died within 30 days of being diagnosed, and more than half of those deaths (15,000) were directly attributable to a C. difficile infection.

Dale Gerding, MD, FACP, FIDSA joins 25+ internationally recognized experts in health care, academic, and industry leaders to discuss the burden of Clostridium difficile infections (C.difficile, C.diff., CDI) and prevention, treatments, diagnostics, research, clinical trials, with Microbiome research, Infection Prevention, Irritable Bowel Syndrome treatments and clinical trials, Environmental Safety, Fecal Microbiota Restoration, Antibiotic Stewardship and more.

To learn more about the program and guest speakers: https://cdifffoundation.org/cdiff2017guest-speakers/

All attendees will have the highest levels of peer networking and learning opportunity at the International C.diff. Awareness Conference and Health EXPO. The conference program builds in time for face-to-face interaction between attending executives, corporate representatives and industry experts exhibiting at the health expo.

Attendee Linda Jablonski, RN, BSN said about the 2016 conference, "The information shared at the conference provided up-to-date studies and important information that help us all save lives."

We sincerely thank the following Sponsors for their continued support and for joining the C Diff Foundation in promoting C. diff. Awareness worldwide:
- Diamond: Synthetic Biologics.
- Gold: Clorox Healthcare, Seres Therapeutics, ROCHE, Rebiotix, Nestle Health Science, Xenex.
- Silver: SporeGen, Tru-D, Pfizer, Environmental Disinfection Management, Surfacide.
- Conference Shuttles Sponsored by Sterilize RD (tm) RAPID UVC DISINFECTOR.

We would also like to thank the following organizations:
* This conference is supported through an educational grant from Sanofi Pasteur US.
* This activity has been supported by an independent patient advocacy grant from Merck & Co., Inc.

Visit https://cdifffoundation.org for more information. Contact Denise Graham for registration and media inquiries denise@cdifffoundation.org or Mobile (202)-294-6314.

About the C Diff Foundation:

The C Diff Foundation, a 501(c)(3) established 2012, comprised of 100 percent volunteering professionals dedicated at supporting public health through education and advocating for C. difficile infection (CDI) prevention, treatments, environmental safety, and support worldwide.

Follow C Diff Foundation on Twitter
@cdiffFoundation
#Cdiff2017

*LOGO for media: Send2Press.com/300dpi/17-0816s2p-2017CdiffConfLogo-300dpi.jpg

The C Diff Foundation welcomes Dale Gerding, MD, FACP, FIDSA, and Professor of Medicine at Loyola University Chicago Stritch School of Medicine in Maywood, Illinois and Research Physician at the Edward Hines Jr. VA Hospital as Conference Chair of the upcoming 5th Annual International "C.diff. Awareness Conference and Health EXPO," taking place on Nov. 9 and 10, 2017 at the University of Nevada - Las Vegas, Thomas and Mack Center, 2nd Floor Pavilion.

Related link: https://cdifffoundation.org/

Edmond Hooker, MD, Darrel Hicks, and Bruce Rippe Discuss Medical Mattress Contamination Issues on C.diff Spores and More, Aug. 1

TAMPA, Fla. /ScoopCloud/ -- C Diff Foundation's, "C. diff. Spores and More Global Broadcasting Network," is honored to announce Dr. Edmond Hooker, MD - Associate Professor of Health Services Administration at Xavier University, Darrel Hicks, a well-known hospital environment specialist and educator, and Bruce Rippe, CEO of Trinity Guardion, manufacturer of the Trinity Guardion Patient Protective Barrier, as our guest speakers on August 1, 2017 at 10 a.m. PT / 1 p.m. ET on www.cdiffradio.com.

These leading topic experts will be discussing Dr. Hooker's Clostridium difficile (C. diff.) research related to hospital beds and mattresses, the issues that prevent successful disinfection of soft mattress surfaces, the new regulatory landscape, and the proven solution to the problem. The data being shared will be beneficial to hospital nursing officers, infection preventionists, and environmental services professionals. Many healthcare professionals are unaware that hospital beds, which are the epicenter of patient care, can also be the epicenter of potentially life-threatening cross-contamination.

Trinity Guardion's patient protective microbarrier is the first and only launderable and reusable mattress cover system specifically for medical beds. It's designed to protect each patient and prolong the useful life of expensive high-tech hospital mattresses, by shielding the mattress and bed deck from every previous occupant's microbial biome. More importantly, it protects each patient from residual pathogenic organisms such as C. diff., which can cause serious illness and death, and may be present even if previous patients were not symptomatic.

If you miss the live broadcast, access the podcast in the living library and listen at your leisure www.cdiffradio.com.

About Trinity Guardion:
Founded in 2010 and based in Batesville, Indiana, Trinity Guardion manufactures the Trinity Guardion(R) Patient Protective Barrier, the only reusable and launderable cover system for hospital beds and bed decks that is specifically engineered to block and eliminate pathogens such as Clostridium difficile (C. diff.). The system delivers a validated cleaning and disinfection solution that is proven to reduce infection rates.

About the C Diff Foundation:
The C Diff Foundation, a 501(c)(3) non-profit, founded in 2012 by Nancy C. Caralla, a nurse who was diagnosed and treated for Clostridium difficile (C. diff.) infections. Through her own journey and the loss of their father to C. difficile infection involvement, Nancy recognized the need for greater awareness through education about research being conducted by the government, industry, and academia and better advocacy on behalf of patients, healthcare professionals, and researchers worldwide working to address the public health threat posed by this devastating infection.

For information please visit http://www.cdifffoundation.org/.

Media Coordinator
Denise Graham
denise@cdifffoundation.org

C Diff Foundation's, "C. diff. Spores and More Global Broadcasting Network," is honored to announce Dr. Edmond Hooker, MD - Associate Professor of Health Services Administration at Xavier University, Darrel Hicks, a well-known hospital environment specialist and educator, and Bruce Rippe, CEO of Trinity Guardion, manufacturer of the Trinity Guardion Patient Protective Barrier, as our guest speakers on August 1, 2017.

Related link: https://cdifffoundation.org/

Clifford McDonald, MD and Alison Laufer-Halpin, Ph.D., of the CDC Discuss the Human Microbiome on C. diff. Spores and More

ATLANTA, Ga. /ScoopCloud/ -- C Diff Foundation's "C. diff. Spores and More Global Broadcasting Network" is honored to announce Doctors McDonald and Laufer-Halpin as our guest speakers on July 25, 2017 at 10 a.m. PT / 1 p.m. ET on C Diff Radio (www.cdiffradio.com).

These leading topic experts will be discussing significant ways to unlock the mysteries of the human microbiome; how it affects our health, the immune system, and why it is so important to protect it.

As part of the Centers for Disease Control and Prevention (CDC) efforts to protect patients and slow antibiotic-resistance, the CDC is investing in research to discover and develop new ways to prevent antibiotic-resistant infections.

Learn more about C Diff Radio at: http://www.cdiffradio.com/.

About the C Diff Foundation:

The C Diff Foundation, a 501(c)(3) non-profit, founded in 2012 by Nancy C. Caralla, a nurse who was diagnosed and treated for Clostridium difficile (C. diff.) infections.

Through her own journey and the loss of their father to C. difficile infection involvement, Nancy recognized the need for greater awareness through education about research being conducted by the government, industry, and academia and better advocacy on behalf of patients, healthcare professionals, and researchers worldwide working to address the public health threat posed by this devastating infection.

For information please visit https://cdifffoundation.org/.

More information and media queries: info@cdifffoundation.org

C Diff Foundation's "C. diff. Spores and More Global Broadcasting Network" is honored to announce Doctors McDonald and Laufer-Halpin as our guest speakers on July 25, 2017 at 10 a.m. PT / 1 p.m. ET on C Diff Radio.

Related link: https://cdifffoundation.org/

C Diff Foundation Announces Scholarship Program to Support Health Care Students

TAMPA, Fla. /ScoopCloud/ -- The C Diff Foundation is pleased to announce the Michael and Helen Caralla, Sr. Educational Scholarship program. The scholarship program is to help health care students succeed and reach their educational goals.

To apply for a C Diff Foundation; Michael and Helen Caralla, Sr. Educational Scholarship, the applicant must submit an application by May 1 of each calendar year. The C Diff Foundation selection committee chooses application recipients based on a submitted essay, letters of recommendation, a willingness to complete the Volunteer Service project to promote C. difficile infection awareness requirement, and financial need.

Awards consist of annual scholarships that range in value from $750 to $1,500 USD. Recipients must reapply each year they attend post-secondary school and will be chosen based on their academic progress and mentoring performance.

To be eligible for a Michael and Helen Caralla, Sr. Educational Scholarship the applicant must be:
* A student and a high school graduate or have a General Educational Development a.k.a. General Educational Diploma (GED).
* Enrolled full-time at an accredited post-secondary educational institution during the 2017-2018 academic year (If a foreign student is applying and is chosen, the educational scholarship awarded amount will be converted from USD to the educational institute location foreign currency exchange rate and rounded up to the nearest whole dollar).
* Maintain full-time status throughout the 2017-2018 academic year in order to remain eligible.
* Willing to complete a minimum of 50 volunteer hours promoting C. difficile infection prevention, treatments, and environmental safety awareness in their local communities per academic year awarded the educational scholarship.

C. difficile infections can be acquired and diagnosed in infants and across the life-span with a higher risk involving our senior citizens and that is why it is imperative to learn about a C. difficile infection, its most common symptoms, the treatments available, and environmental safety products to prevent the spread of this spore-bacteria and to help reduce C. difficile infection recurrences.

"When you apply to become a C Diff Foundation Scholar, you are taking the first step to determine your own future. The C Diff Foundation Scholars are individuals motivated and dedicated to making a difference in the health care community. We are excited to offer a scholarship program to help support health care students to advance their career path through the Michael and Helen Caralla, Sr. educational scholarship, a program in memory of our loving parents," states Nancy C Caralla, Executive Director.

About the C Diff Foundation:

The C Diff Foundation, a 501(c)(3) non-profit, founded in 2012 by Nancy C Caralla, a nurse diagnosed and treated for Clostridium difficile (C. diff.) infections.

Through her own CDI journeys and witnessing the passing of her father, diagnosed with sepsis secondary to C. difficile infection involvement, Nancy recognized the need for greater awareness through education, the research being conducted by the government, industry, and academia and better advocacy on behalf of patients, healthcare professionals, and researchers worldwide working to address the public health threat posed by this devastating infection.

For additional Scholar Applicant information, visit the C Diff Foundation website: https://cdifffoundation.org/scholarship-eligibility/

Media Coordinator:
Denise Graham, RN, CIC
info@cdifffoundation.org

Twitter: @cdiffFoundation #CdiffScholar

*PHOTO for media: Send2Press.com/mediaboom/17-0711s2p-caralla-300dpi.jpg
*Photo Caption: Michael and Helen Caralla, Sr.

The C Diff Foundation is pleased to announce the Michael and Helen Caralla, Sr. Educational Scholarship program. The scholarship program is to help health care students succeed and reach their educational goals.

Related link: https://cdifffoundation.org/

‘C. diff. Science’ Honors Professionals Dedicated to Clostridium difficile Research and Development

TAMPA, Fla. /ScoopCloud/ -- The C Diff Foundation hosts "C. diff. Science" on Sept. 14 to honor professionals dedicated to the scientific research and development in the Clostridium difficile (C. difficile, C. diff.) community worldwide, chaired by Professor Simon M. Cutting, PhD, of Molecular Microbiology at Royal Holloway, University of London.

The free live webinar will take place from 8 a.m. - 12 p.m. ET, Sept. 14, 2017.

Professor Cutting, Event Chair and guest presenter, shares the platform with seven fellow scientists focused on their contributions involving the most common pathogen identified, and leading healthcare-associated infection (HAI) - Clostridium difficile.

C. difficile infections can be acquired and diagnosed in infants and across the life-span with a higher risk involving our senior citizens and that is why it is imperative to learn about a C. difficile infection, its most common symptoms, the treatments available, and environmental safety products to prevent the spread of this spore-bacteria and to help reduce C. difficile infection recurrences.

"On September 14th fellow professionals in the C. diff. community, and those who share a common interest, will have the opportunity to gain knowledge from scientists around the globe who have dedicated their professional lives researching and developing new concepts, new theories, and the progress towards a better understanding - pursuing future developments in Clostridium difficile (a.k.a., C. difficile, C.diff.) infection prevention, treatments, and environmental safety products worldwide," states Nancy C Caralla, Executive Director.

About the C Diff Foundation:

The C Diff Foundation, a 501(c)(3) non-profit, founded in 2012 by Nancy C Caralla, a nurse diagnosed and treated for Clostridium difficile (C. diff.) infections.

Through her own journeys and witnessing the passing of her father diagnosed with sepsis secondary to C. difficile infection involvement, Nancy recognized the need for greater awareness through education, the research being conducted by the government, industry, and academia and better advocacy on behalf of patients, healthcare professionals, and researchers worldwide working to address the public health threat posed by this devastating infection.

For webinar information contact event coordinators: info@cdiffscience.org and visit the event website: http://cdiffscience.org/ to register for this free webinar.

For C Diff Foundation information please visit: https://cdifffoundation.org/.

Media Contact Person:
Nancy Caralla
ncaralla@cdifffoundation.org

*LOGO: https://cdifffoundation.files.wordpress.com/2013/06/cdifflogoadjdtrd.jpg

Twitter: @cdiffFoundation #CDiffScience

The C Diff Foundation hosts "C. diff. Science" on Sept. 14 to honor professionals dedicated to the scientific research and development in the Clostridium difficile (C. difficile, C. diff.) community worldwide, chaired by Professor Simon M. Cutting, PhD, of Molecular Microbiology at Royal Holloway, University of London.

Bake Sale to Raise C. diff. Awareness Starts in Florida Before Volunteers Roll-out Worldwide

TAMPA, Fla. /ScoopCloud/ -- C Diff Foundation announces its "Bake Sale for C.diff. Awareness," a month-long campaign beginning May 2017 in Florida and continuing in N.J., N.C., and across the USA to India, and Italy featuring education and advocacy on health care topics pertaining to the most common pathogen identified as a leading healthcare-associated infection (HAI) in U.S. hospitals alone: Clostridium difficile.

You know how when you are trying to promote Clostridium difficile (C.diff.) awareness, you run into obstacles - such as information resistance and lack of concern.

We have experienced it, learned from it, and developed new roads to successfully accomplish the goal to effectively promote C.difficile infection (CDI) awareness prevention, treatments, environmental safety, and support available.

Nearly half a million Americans suffer from Clostridium difficile (C. diff.) infections in a single year according to a study released February 2015 by the Centers for Disease Control and Prevention (CDC). About 15,000 deaths were estimated to be directly attributable to C. diff. infections.

Previous studies indicate that C. diff. has become the most common microbial cause of healthcare-associated infections found in U.S. hospitals driving up costs to $4.8 billion each year.

The C Diff Foundation takes it to a different level to promote the message and receive the audience's nod generously donating funds to support educational patient programs offered. We do this by having residents share in a common-interest event - a "Bake Sale for C. diff. Awareness."

Who are the audiences? They are you, neighbors, local health care professionals, local service operators -- both students and faculty -- and individuals with a will to join the events to learn about a C. difficile infection because it can be acquired by anyone and has no boundaries.

At first the residents, health care professionals, and local service professionals show resistance to listen about how a gastrointestinal infection, that they have never experienced, can cause such pain and tragic losses.

Once they are introduced to Kathy, Nancy, Lisa, Roy, Scott, Angelo, Tonia, Renetta, Gary, Deborah, and thousands of other Clostridium difficile (C.diff.) Survivors (www.cdiffsurvivors.org) and hear their heart-breaking C. difficile infection journeys - the door swings open and the understanding takes hold.

As a result, we witness an exchange of important information with the positive outcome of understanding how dangerous a C. difficile infection can be, how important it is to have a conversation with health care providers about the use of antibiotics to treat respiratory, urinary, and dental symptoms, how to manage the care of a C. diff. infection at home, and support sessions that are free and available by phone to everyone needing a voice that understands able to guide families worldwide.

"The Worldwide Bake Sale for C.diff. Awareness campaign was insight-based. We know that the health message alone does not work, and felt that making our message appearance-based, with personal participation it would make the educational facet more relevant to our audiences," states Nancy C Caralla, Executive Director. "Who doesn't like to enjoy Grandma's chocolate chip cookies? Sharing, caring, and bringing it face-to-face with a blend of history is the recipe of our success in promoting C. difficile infection prevention, treatments, environmental safety, and support worldwide."

About the C Diff Foundation:

The C Diff Foundation, a 501(c)(3) established 2012, is comprised of 100 percent volunteering professionals dedicated at supporting public health through education and advocating for C. difficile infection (CDI) prevention, treatments, environmental safety, and support worldwide.

The Foundress, Nancy C. Caralla, a Nurse diagnosed and treated for Clostridium difficile (C. diff.) infections and witnessing the loss of her father to C. difficile infection involvement, Nancy recognized the need for greater awareness through education, about research being conducted by the government, industry, and academia and better advocacy on behalf of patients, healthcare professionals, and researchers worldwide working to address the public health threat posed by this devastating, life-threatening infection.

For information please visit http://www.cdifffoundation.org/

Media Contact Person: Nancy Caralla, ncaralla@cdifffoundation.org

*PHOTO for media: Send2Press.com/mediaboom/17-0504s2p-cdiffbake-300dpi.jpg

C Diff Foundation announces its "Bake Sale for C.diff. Awareness," a month-long campaign beginning May 2017 in Florida and continuing in N.J., N.C., and across the USA to India, and Italy featuring education and advocacy on health care topics pertaining to the most common pathogen identified as a leading healthcare-associated infection (HAI) in U.S. hospitals alone: Clostridium difficile.